熊本大学大学院生命科学研究部 製剤設計学分野

  • ホームホーム
  • 研究室案内研究室案内
  • メンバーメンバー
  • 研究業績研究業績
  • 学位取得者学位取得者
  • 大学院入学希望者の方へ大学院入学希望者の方へ
  • 同門会同門会
  • フォトアルバムフォトアルバム
  • 製剤製造ラボ製剤製造ラボ
  • 関連リンク関連リンク

研究業績

  1. Design and evaluation of a supramolecular boron compound using a cyclodextrin-based polyrotaxane for boron neutron capture therapy.
    Y. Matsumoto, H. Arase, H. Ishiki, H. Takeuchi, Y. Sugawara, T. Taharabaru, R. Onodera, M. Suzuki, A. Nakaie, H. Sakurai, K. Motoyama, T. Higashi
    Carbohydr. Polym., in press (2025).
  2. Novel vial-inner-surface treatment technology improves chemical durability and vial-inner-surface uniformity to reduce drug adsorption on the vial.
    N. Miyamoto, K. Ohsugi, T. Higashi, K. Motoyama
    Chem. Pharm. Bull., in press (2025).
  3. Synthesis of cyclodextrin-based polyrotaxanes and polycatenanes for supramolecular pharmaceutical sciences.
    T. Higashi, T. Taharabaru, K. Motoyama
    Carbohydr. Polym., 337, 122143 (2024).
  4. Sustained release formulation of hydroxypropyl-β-cyclodextrin eye drops using xanthan gum.
    T. Higashi, T. Goto, R. Onodera, T. Hirotsu, H. Ohasi Ikeda, K. Motoyama
    Chem. Pharm. Bull., 72, 381-384 (2024).
  5. Cyclodextrin-based tailored polyrotaxanes for highly efficient delivery of the genome-editing molecule.
    T. Taharabaru, T. Kihara, A. Obata, R. Onodera, Y. Wen, J. Li, K. Motoyama, T. Higashi
    Carbohydr. Polym., 323, 121443 (2024).
  6. Folate-appended hydroxypropyl-β-cyclodextrin induces autophagic cell death in acute myeloid leukemia cells.
    Y. Kubota, T. Hoshiko, T. Higashi, K. Motoyama, S. Okada, S. Kimura
    Int. J. Mol. Sci., 16720 (2023).
  7. Zero-waste preparation of supramolecular hydrogels and films comprising tannic acid and ultra-high-molecular-weight polyethylene oxide.
    Y. Goto, A. Obata, M. Inoue, T. Taharabaru, T. Kihara, R. Onodera, D. Iohara, M. Takafuji, K. Motoyama, T. Higashi
    Res. Mater., 19, 100425 (2023).
  8. Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann-Pick disease type C treatment.
    Y. Yamada, M. Fukaura-Nishizawa, A. Nishiyama, A. Ishii, T. Kawata, A. Shirakawa, M. Tanaka, Y. Kondo, T. Takeo, N. Nakagata, T. Miwa, H. Takeda, Y. Orita, K. Motoyama, T. Higashi, H. Arima, T. Seki, Y. Kurauchi, H. Katsuki, K. Higaki, K. Minami, N. Yoshikawa, R. Ikeda, M. Matsuo, T. Irie, Y. Ishitsuka
    Clin. Transl. Med., 13, e1350 (2023).
  9. Tannic acid-based sustained-release system for protein drugs.
    K. Utatsu, K. Motoyama, T. Nakamura, R. Onodera, T. Higashi
    Int. J. Pharm., 643, 123229 (2023).
  10. Versatile delivery platform for nucleic acids, negatively charged protein drugs, and genome-editing ribonucleoproteins using a multi-step transformable polyrotaxane.
    T. Taharabaru, T. Kihara, R. Onodera, T. Kogo, Y. Wen, J. Li, K. Motoyama, T. Higashi
    Mater. Today Bio, 20, 100690 (2023).
  11. Mannose-methyl-β-cyclodextrin suppresses tumor growth of colon cancer by targeting tumor-associated macrophages.
    Y. Ohno, M. Toshino, A. F. A. Mohammed, Y. Fujiwara, Y. Komohara, R. Onodera, T. Higashi, K. Motoyama
    Carbohydr. Polym., 305, 125551 (2023).
  12. Nanoparticle composites of folic acid-modified methyl-β-cyclodextrin and adamantane/human serum albumin for enhanced antitumor activity.
    A. Sakai, Y. Yamashita, S. Misumi, N. Kishimoto, R. Onodera, T. Higashi, H. Arima, K. Motoyama
    FEBS Open Bio., 13, 233-245 (2023).
  13. Antigen stabilizing hydrogels based on cyclodextrins and polyethylene glycol act as type-2 adjuvants with suppressed local irritation.
    T. Hayashi, F. Nakagawa, Y. Ohno, Y. Suzuki, H. Ishiki, R. Onodera, T. Higashi, Y. Shimamura, H. Itou, Y. Iwase, H. Arima, K. Motoyama
    Eur. J. Pharm. Biopharm., 181, 113-121 (2022).
  14. Stabilization and movable ligand-modification by folate-appended polyrotaxanes for systemic delivery of siRNA polyplex.
    A. F. A. Mohammed, M. H. Othman, T. Taharabaru, K. M. Elamin, K. Ito, M. Inoue, M. El-Badry, K. I. Saleh, R. Onodera, K. Motoyama, T. Higashi
    ACS Macro Lett., 11, 1225-1229 (2022).
  15. Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann-Pick disease type C without hearing loss.
    Y. Yamada, T. Miwa, M, Nakashima, A, Shirakawa, N. Namba, Y. Kondo, T. Takeo, N. Nakagata, K. Motoyama, T. Higashi, H. Arima, Y. Kurauchi, T. Seki, H. Katsuki, Y. Okada, A. Ichikawa, K. Higaki, K. Hayashi, K. Minami, N. Yoshikawa, R. Ikeda, Y. Ishikawa, T. Kajii, K. Tachii, H. Takeda, Y. Orita, M. Matsuo, T. Irie, Y. Ishitsuka
    Biomed. Pharmacother., 155, 113698 (2022).
  16. Multifunctional therapeutic cyclodextrin-appended dendrimer complex for treatment of systemic and localized amyloidosis.
    M. Inoue, T. Higashi, Y. Hayash, R. Onodera, K. Fujisawa, T. Taharabaru, R. Yokoyama, K. Ouchi, Y. Misumi, M. Ueda, Y. Inoue, M. Mizuguchi, T. Saito, T. Saido, Y. Ando, H. Arima, K. Motoyama, H. Jono
    ACS Appl. Mater. Interfaces, 14, 40599-40611 (2022).
  17. Feasibility study of Dendrimer-based TTR-CRISPR pDNA polyplex for ocular amyloidosis in vitro.
    M. Inoue, K. Muta, A. F. A. Mohammed, R. Onodera, T. Higashi, K. Ouchi, M. Ueda, Y. Ando, H. Arima, H. Jono, K. Motoyama
    Biol. Pharm. Bull., 45, 1660-1668 (2022).
  18. Colletofragarone A2 Inhibits Cancer Cell Growth In Vivo Leads to the Degradation and Aggregation of Mutant p53.
    Y. Sadahiro, Y. Hitora, I. Kimura, N. Hitora-Imamura, R. Onodera, K. Motoyama, S. Tsukamoto
    Chem. Res. Toxicol., 9, 1598-1603 (2022).
  19. Application of cyclodextrin/polyethylene glycol in blood-storage tools for liquid biopsy.
    F. Nakagawa, Y. Shimamura, Y. Suzuki, T. Taharabaru, H. Itou, Y. Iwase, R. Onodera, T. Higashi, K. Motoyama
    Mater. Lett., 324, 132660 (2022).
  20. A 'human and mouse cross-reactive' albumin-binding helix-loop-helix peptide tag for prolonged bioactivity of therapeutic proteins.
    Y. Nakatani, Z. Ye, Y. Ishizue, T. Higashi, T. Imai, I. Fujii, M. Michigami
    Mol. Pharm.    , 19, 2279-2286 (2022).
  21. Lactose-appended hydroxypropyl-β-cyclodextrin Lowers Cholesterol Accumulation and Alleviates Motor Dysfunction in Niemann-Pick Type C Disease Model Mice.
    T. Nishida, R. Yokoyama, Y. Kubohira, Y. Maeda, T. Takeo, N. Nakagata, H. Takagi, K. Ishikura, K. Yanagihara, S. Misumi, N. Kishimoto, Y. Ishitsuka, Y. Kondo, T. Irie, M. Soga, T. Era, R. Onodera, T. Higashi, K. Motoyama
    ACS Appl. Bio Mater., 5, 2377-2388 (2022).
  22. Cyclodextrin-based catenanes and polycatenanes.
    T. Higashi, K. Motoyama, J. Li
    J. Incl. Phenom. Macro. Chem., 102, 569-575 (2022).
  23. Polyrotaxane-based multi-step transformable materials for the delivery of Cas9 ribonucleoprotein.
    T. Taharabaru, T. Kihara, R. Onodera, T. Kogo, K. Higashi, K. Moribe, T. Nakamura, K. Motoyama, T. Higashi
    Appl. Mater. Today, 27, 101488 (2022).
  24. The effects of sacran, a sulfated polysaccharide, on the gut microbiota using chronic kidney disease model rats.
    M. Goto, Y. Kobira, S. Kaneko, H. Arima, A. Michihara, K. Azuma, T. Higashi, K. Motoyama, H. Watanabe, T. Maruyama, D. Kadowaki, M. Otagiri, D. Iohara, F. Hirayama, M. Anraku
    Biol. Pharm. Bull., 45, 576-582 (2022).
  25. Polyrotaxane-based supramolecular material for improvement of pharmaceutical properties of protein drugs.
    T. Kogo, K. Utatsu, T. Taharabaru, R. Onodera, K. Motoyama, T. Higashi
    J. Pharm. Sci., 111, 2116-2120 (2022).
  26. Hydroxypropyl-β-cyclodextrin Enhances Oral Absorption of Silymarin Nanoparticles Prepared Using PureNano™ Continuous Crystallizer.
    R. Onodera, T. Hayashi, K. Motoyama, K. Tahara, H. Takeuchi
    Pharmaceutics, 14, 394 (2022).
  27. Design and evaluation of folate-modified liposomes for pulmonary administration in lung cancer therapy.
    R. Onodera, S. Morioka, S. Unida, K. Motoyama, K. Tahara, H. Takeuchi
    Eur. J. Pharm. Sci., 168, 106081 (2022).
  28. The effect of folate‑appended methyl‑β‑cyclodextrin increases on survival rates in a peritoneal dissemination mouse models of human ovarian cancer.
    R. Onodera, A. Sakai, A. Tokuda, T. Higashi, K. Motoyama
    J. Incl. Phenom. Macro. Chem., 102, 143-149 (2022).
  29. pH-sensitive multi-drug liposomes targeting folate receptor β for efficient treatment of non-small cell lung cancer.
    Park YI, Kwon SH, Lee G, Motoyama K, Kim MW, Lin M, Niidome T, Choi JH, Lee R.
    J. Control. Release, 330, 1-14, (2021).
  30. Supramolecular polymer-based transformable material for reversible PEGylation of protein drugs.
    K. Utatsu, T. Kogo, T. Taharabaru, R. Onodera, K. Motoyama, T. Higashi
    Mater. Today Bio, 12, 100160 (2021).
  31. Folic acid-appended hydroxypropyl-β-cyclodextrin exhibits potent antitumor activity in chronic myeloid leukemia cells via autophagic cell death.
    T. Hoshiko, Y. Kubota, R. Onodera, T. Higashi, M. Yokoo, K. Motoyama, S. Kimura
    Cancers, 13, 5413 (2021).
  32. Fasting impairs type 2 helper T cell infiltration in the lung of an eosinophilic asthma mouse model.
    Y. Suzuki, T. Hayashi, R. Yokoyama, F. Nakagawa, J. Inoue, T. Higashi, R. Onodera, K. Motoyama
    FEBS Open Bio, 11, 2619-2630 (2021).
  33. Synthesis of cyclodextrin‐based radial polycatenane cyclized by amide bond and subsequent fabrication of water‐soluble derivatives.
    K. Morita, K. Motoyama, A. Kuramoto, R. Onodera, T. Higashi
    J. Incl. Phenom. Macro. Chem., 100, 169-175 (2021).
  34. The Potential Cytotoxic Activity Enhancement of α-Mangostin in Chitosan-Kappa Carrageenan-Loaded Nanoparticle against MCF-7 Cell Line.
    N. Wathoni, L. Meylina, A. Rusdin, A.F.A. Mohammed, D. Tirtamie, Y. Herdiana, K. Motoyama, C. Panatarani, I.M. Joni, R. Lesmana, M. Muchtaridi
    Polymers, 13, 1681 (2021).
  35. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins impacts safety margin in treating Niemann-Pick disease type C.
    Y. Yamada, Y. Ishitsuka, Y. Kondo, S. Nakahara, A. Nishiyama, T. Takeo, N. Nakagata, K. Motoyama, T. Higashi, H. Arima, S. Kamei, T. Shuto, Tsuyoshi, H. Kai, Y. Hayashino, M. Sugita, T. Kikuchi, F. Hirata, T. Miwa, H. Takeda, Y. Orita, T. Seki, T. Ohta, Y. Kurauchi, H. Katsuki, M. Matsuo, K. Higaki, K. Ohno, S. Matsumoto, T. Era, T. Irie
    Br. J. Pharmacol., 178, 2727-2746 (2021).
  36. Control strategy and methods for continuous direct compression processes.
    Y. Suzuki, H. Sugiyama, M. Kano, R. Shimono, G. Shimada, R. Furukawa, E. Mano, K. Motoyama, T. Koide, Y. Matsui, K. Kurasaki, I. Takayama, S. Hikage, N. Katori, M. Kikuchi, H. Sakai, Y. Matsuda
    Asian. J. Pharm. Sci., 16, 253-262 (2021).
  37. Computational screening of a functional cyclodextrin derivative for suppressing a side-effect of doxorubicin.
    M. Sugita, I. Kuwano, T. Higashi, K. Motoyama, H. Arima, F. Hirata
    J. Phys. Chem. B, 125, 2308-2316 (2021).
  38. Polypseudorotaxane-based supramolecular hydrogels consisting of cyclodextrins and Pluronics as stabilizing agents for antibody drugs.
    N. Ohshita, K. Motoyama, D. Iohara, F. Hirayama, T. Taharabaru, N. Watabe, Y. Kawabata, R. Onodera, T. Higashi
    Carbohydr. Polym., 256, 117419 (2021).
  39. Sacran, a sulfated polysaccharide, adsorbs triglyceride and modulates the intestinal flora in the gut in non-alcoholic steatohepatitis model rats.
    M. Goto, K. Azuma, H. Arima, S. Kaneko, T. Higashi, K. Motoyama, A. Michihara, T. Shimizu, T. Maruyama, M. Otagiri, D. Iohara, F. Hirayama, M. Anraku
    Life Sci., 268, 118991 (2021).
  40. Intracerebroventricular treatment with 2-hydroxypropyl-β-cyclodextrin decreased cerebellar and hepatic glycoprotein nonmetastatic melanoma protein B (GPNMB) expression in Niemann-Pick disease type C model mice.
    M. Fukaura, Y. Ishitsuka, S. Shirakawa, N. Ushihama, Y. Yamada, Y. Kondo, T. Takeo, N. Nakagata, K. Motoyama, T. Higashi, H. Arima, Y. Kurauchi, T. Seki, H. Katsuki, K. Higaki, M. Matsuo, T. Irie
    Int. J. Mol. Sci., 22, 452 (2021).
  41. Enteric-Coated Strategies in Colorectal Cancer Nanoparticle Drug Delivery System.
    Wathoni N, Nguyen AN, Rusdin A, Umar AK, Mohammed AFA, Motoyama K, Joni IM, Muchtaridi M.
    Drug Des Devel Ther., 14, 4387-4405 (2020).
  42. Enhancement of α-Mangostin Wound Healing Ability by Complexation with 2-Hydroxypropyl-β-Cyclodextrin in Hydrogel Formulation.
    Wathoni N, Sari DP, Suharyani I, Motoyama K, Mohammed AFA, Cahyanto A, Abdassah M, Muchtaridi M.
    Pharmaceuticals. 13(10):290 (2020).
  43. Lactose-appended β-cyclodextrin as an effective nanocarrier for brain delivery.
    R. Yokoyama, T. Taharabaru, T. Nishida, Y. Ohno, Y. Maeda, M. Sato, K. Ishikura, K. Yanagihara, H. Takagi, T. Nakamura, S. Ito, S. Ohtsuki, H. Arima, R. Onodera, T. Higashi, K. Motoyama
    J. Control. Release, 328, 722-735 (2020).
  44. Improvement of pharmaceutical properties of Zerumbone, a multifunctional compound, using cyclodextrin derivatives.
    Md. M. Hassan, A.F.A. Mohammed, K.M. Elamin, H.P. Devkota, Y. Ohno, K. Motoyama, T. Higashi, T. Imai
    Chem. Pharm. Bull., 68, 1117-1120 (2020).
  45. Efficient anticancer drug delivery for pancreatic cancer treatment utilizing supramolecular polyethylene-glycosylated bromelain.
    T. Higashi, T. Kogo, N. Sato, T. Hirotsu, S. Misumi, H. Nakamura, D. Iohara, R. Onodera, K. Motoyama, H. Arima
    ACS Appl. Bio Mater., 3, 3005-3014 (2020).
  46. Folate-appended cyclodextrin improves the intratumoral accumulation of existing boron compounds.
    Y. Matsumoto, K. Hattori, H. Arima, K. Motoyama, T. Higashi, H. Ishikawa, N. Fukumitsu, T. Aihara, K. Nakai, H. Kumada, H. Sakurai
    Appl. Radiat. Isot., 163, 109201 (2020).
  47. Genome editing in a wide area of the brain using dendrimer-based ternary polyplexes of Cas9 ribonucleoprotein.
    T. Taharabaru, R. Yokoyama, T. Higashi, A.F.A. Mohammed, M. Inoue, Y. Maeda, T. Niidome, R. Onodera, K. Motoyama
    ACS Appl. Mater. Interfaces, 12, 21386-21397 (2020).
  48. Differential effects of 2-hydroxypropyl-cyclodextrins on lipid accumulation in Npc1-null cells.
    S. Hoque, Y. Kondo, N. Sakata, Y. Yamada, M. Fukaura, T. Higashi, K. Motoyama, H. Arima, K. Higaki, A. Hayashi, T. Komiya, Y. Ishitsuka, T. Irie
    Int. J. Mol. Sci., 21, 898 (2020).
  49. Nanoparticle drug delivery systems for α-mangostin.
    N. Wathoni, A. Rusdin, K. Motoyama, I.M. Joni, R. Lesmana, M. Muchtaridi
    Nanotechnol. Sci. Appl., 13, 23-36 (2020).
  50. Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer.
    R. Lee, Y.J Choi, M.y.S Jeong, Y.Il. Park, K. Motoyama, M.W. Kim, S.H. Kwon, J.H. Choi
    Bioconjug. Chem., 31, 923-932 (2020).
  51. A thermoresponsive hydrophobically modified hydroxypropylmethyl cellulose/cyclodextrin injectable hydrogel for the sustained release of drugs.
    M. Okubo, D. Iohara, M. Anraku, T. Higashi, K. Uekama, F. Hirayama
    Int. J. Pharm., 575, 118845 (2020).
  52. Formulation and Characterization of α-Mangostin in Chitosan Nanoparticles Coated by Sodium Alginate, Sodium Silicate, and Polyethylene Glycol.
    Wathoni N, Rusdin A, Febriani E, Purnama D, Daulay W, Azhary SY, Panatarani C, Joni IM, Lesmana R, Motoyama K, Muchtaridi M.
    J Pharm Bioallied Sci., 11, S619-S627 (2019)
  53. Identification of candidate molecular targets of the novel antineoplastic antimitotic NP-10.
    T. Yokoyama, M. Yukuhiro, Y. Iwasaki, C. Tanaka, K. Sankoda, R. Fujiwara, A. Shibuta, T. Higashi, K. Motoyama, H. Arima, K. Yoshida, N. Sugimoto, H. Morimoto, H. Kosako, T. Ohshima, M. Fujita
    Sci. Rep., 9, 16825 (2019).
  54. Hepatocyte-targeted delivery of siRNA polyplex with PEG-modified lactosylated dendrimer/cyclodextrin conjugates for transthyretin-related amyloidosis therapy.
    Y. Hayashi, T. Higashi, K. Motoyama, H. Jono, Y. Ando, H. Arima
    Biol. Pharm. Bull., 42, 1679-1688 (2019).
  55. A comprehensive understanding of lowly-hydrolyzed polyvinyl alcohol based ternary solid dispersions by application of a combined mixture experimental design.
    Y. Mori, T. Higashi, K. Motoyama, M. Ishida, R. Onodera, H. Arima
    Drug Dev. Ind. Pharm., 45, 1599-1609 (2019).
  56. One-pot synthesis of cyclodextrin-based radial poly[n]catenanes.
    T. Higashi, K. Morita, X. Song, J. Zhu, A. Tamura, N. Yui, K. Motoyama, H. Arima, J. Li
    Commun. Chem., 2, 78 (2019).
  57. In vivo efficacy and safety evaluation of lactosyl-β-cyclodextrin as a therapeutic agent for hepatomegaly in Niemann-Pick Type C disease.
    Y. Maeda, K. Motoyama, R. Nishiyama, T. Higashi, R. Onodera, H. Nakamura, T. Takeo, N. Nakagata, Y. Yamagata, Y. Ishitsuka, Y. Kondo, T. Irie, T. Era, H. Arima
    Nanomaterials, 9, 802 (2019).
  58. In vitro and in vivo co-delivery of siRNA and doxorubicin by folate-PEG-appended dendrimer/glucuronylglucosyl-β-cyclodextrin conjugate.
    A.F. Abdelwahab, T. Higashi, K. Motoyama, A. Ohyama, R. Onodera, K.A. Khaled, H.A. Sarhan, A.K. Hussein, H. Arima
    AAPS J., 21, 1-10 (2019).
  59. Therapeutic potential of PAMAM dendrimer for amyloidogenic transthyretin amyloidosis.
    M. Inoue, M. Ueda, T. Higashi, T. Anno, K. Fujisawa, K. Motoyama, M. Mizuguchi, Y. Ando, H. Jono, H. Arima
    ACS Chem. Neurosci., 10, 2584-2590 (2019).
  60. In vitro and in vivo evaluation of 6-O-a-maltosyl-β-cyclodextrin as a potential therapeutic agent against Niemann-Pick disease Type C.
    N. Yasmin, Y. Ishitsuka, M. Fukaura, Y. Yamada, S. Nakahara, A. Ishii, Y. Kondo, T. Takeo, N. Nakagata, K. Motoyama, T. Higashi, Y. Okada, J. Nishikawa, A. Ichikawa, D. Iohara, F. Hirayama, K. Higaki, K. Ohno, M. Matsuo, T. Irie
    Int. J. Mol. Sci., 20, E1152 (2019).
  61. Cyclodextrin-based molecular accessories for drug discovery and drug delivery.
    T. Higashi
    Chem. Pharm. Bull., 67, 289-298 (2019). *Selected as a "Featured Article".
  62. Targeted siRNA delivery to tumor cells by folate-PEG-appended dendrimer/glucuronylglucosyl-β-cyclodextrin conjugate.
    A.F. Abdelwahab, T. Higashi, K. Motoyama, A. Ohyama, R. Onodera, K.A. Khaled, H.A. Sarhan, A.K. Hussein, H. Arima
    J. Incl. Phenom. Macro. Chem., 93, 41-52 (2019).
  63. Lowering effect of dimethyl-a-cyclodextrin on GM1-ganglioside accumulation in GM1-gangliosidosis model cells and in brain of β-galactosidase-knockout mice.
    Y. Maeda, K. Motoyama, T. Higashi, R. Onodera, T. Takeo, N. Nakagata, Y. Kurauchi, H. Katsuki, Y. Ishitsuka, Y. Kondo, T. Irie, T. Era, H. Arima,
    J. Incl. Phenom. Macro. Chem., 93, 53-66 (2019).
  64. Theoretical and practical evaluation of lowly hydrolyzed polyvinyl alcohol as a potential carrier for hot-melt extrusion,
    Y. Mori, K. Motoyama, M. Ishida, R. Onodera, T. Higashi, H. Arima
    Int. J. Pharm., 555, 124-134 (2019).
  65. DAMP-inducing adjuvant and PAMP adjuvants parallelly enhance protective type-2 and type-1 immune responses to influenza split vaccination,
    T. Hayashi, E. Kuroda, T. Kusakabe, M. Momota, S. Kobari, K. Makisaka, Y. Ohno, Y. Suzuki, F. Nakagawa, M.S.J. Lee, C. Coban, R. Onodera, T. Higashi, K. Motoyama, K.J. Ishii, H. Arima
    Front. Immunol., 9, 1-14 (2018).
  66. Sacran, a high-molecular weight polysaccharide inhibits renal injury and oxidative stress in chronic renal failure model rats.
    M. Goto, D. Iohara, S. Kaneko, T. Higashi, K. Motoyama, T. Maruyama, K. Uekama, F. Hirayama, M. Otagiri, M. Anraku
    J. Nutri. Bio., 4, 267-275 (2018).
  67. Identification of molecular-interaction sites between lowly hydrolyzed polyvinyl alcohols and indomethacin by NMR spectroscopy.
    Y. Mori, M. Takahashi, Y. Ohno, R. Okura, M. Ishida, T. Higashi, K. Motoyama, H. Arima
    Int. J. Pharm., 549, 456-465 (2018).
  68. Supramolecular pharmaceutical sciences: A novel concept combining pharmaceutical sciences and supramolecular chemistry with focus on cyclodextrin-based supermolecules.
    T. Higashi, D. Iohara, K. Motoyama, H. Arima
    Chem. Pharm. Bull., 66, 207-216 (2018). *Selected as a cover article
  69. Sacran: Novel natural sulfated polysaccharide as anti-allergic skincare biomaterial for atopic dermatitis.
    K. Motoyama, T. Higashi, N.R. Ngatu, M.K. Okajima, Y. Nishimura, H. Arima, T. Kaneko
    Occupational & Environmental Skin Diseases, Springer Japan, Tokyo, 79-92 (2018).
  70. Promising use of cyclodextrin-based non-viral vectors for gene and oligonucleotide drugs.
    A.F. Abdelwahab, K. Motoyama, T. Higashi, H. Arima,
    Cyclodextrin, InTech, London, Chapter 10, 239-261 (2018).
  71. Dual targeting system by supramolecular complex of folate-conjugated methyl-b-cyclodextrin with adamantane-grafted hyaluronic acid for the treatment of colorectal cancer.
    K.M. Elamin, K. Motoyama, T. Higashi, Y. Yamashita, A. Tokuda, H. Arima.
    Int. J. Biol. Macromol., 113, 386-394 (2018).
  72. Supramolecular complex of methyl-b-cyclodextrin with adamantane-grafted hyaluronic acid as a novel antitumor agent
    K.M. Elamin, T. Higashi, K. Motoyama, Y. Yamashita, H. Arima
    Chem. Pharm. Bull., 66(3), 277-285 (2018).
  73. Anti-allergic Effects of Novel Sulfated Polysaccharide Sacran on Mouse Model of 2,4-Dinitro-1-fluorobenzene-induced Atopic Dermatitis
    K. Motoyama, Y. Tanida, A. Sakai, T. Higashi, S. Kaneko, H. Arima
    Int. J. Biol. Macromol., 108, 112-118 (2018).
  74. Role of 6-O- a-maltosyl- b-cyclodextrin in lysosomal cholesterol deprivation in Npc1-deficient Chinese hamster ovary cells
    Y. Okada, E. Ueda, Y. Kondo, Y. Ishitsuka, T. Irie, T. Higashi, K. Motoyama, H. Arima, M. Matuso, K. Higaki, K. Ohno, J. Nishikawa, A. Ichikawa
    Carbohydr. Res. , 455, 54-61 (2018).
  75. In vitro and in vivo siRNA delivery to hepatocyte utilizing ternary complexation of lactosylated dendrimer/cyclodextrin conjugates, siRNA and low-molecular-weight sacran
    Y. Hayashi, T. Higashi, K. Motoyama, H. Jono, Y. Ando, H. Arima
    Int. J. Biol. Macromol., 117(Pt A), 1113-1121 (2018).
  76. Involvement of mitophagy-mediated cell death in colon cancer cells by folate-appended methyl-b-cyclodextrin
    K.M. Elamin, Y. Yamashita, K. Motoyama, T. Higashi, H. Arima
    J. Incl. Phenom. Macro. Chem, 89, 333-342 (2017).
  77. Comparison of ovalbumin and ovalbumin epitope peptide for transdermal delivery and vaccination mediated by the photothermal effect of gold nanorods
    A.T. Haine, Y. Miyamoto, T. Higashi, K. Motoyama, H. Arima, T. Niidome
    J. Biomater. Sci. Polym., 28(16), 1888-1898 (2017).
  78. A clue to unprecedented strategy to HIV eradication:"Lock-in and apoptosis"
    H. Tateishi, K. Monde, K. Anraku, R. Koga, Y. Hayashi, H.I. Ciftci, H. DeMirci, T. Higashi, K. Motoyama, H. Arima, M. Otsuka, M. Fujita
    Sci. Rep., 7(1), 8957 (2017).
  79. Sustained Release System of siRNA Complex with Polyethylene glycol-appended a-Cyclodextrin/dendrimer Conjugate from Cyclodextrin Polypseudorotaxanes
    K. Morita, K. Motoyama, T. Higashi, K. Hayashida, I.I. Abu Hashim, H. Arima
    J. Drug Des. Res., 4(6) 1056 1-7 (2017).
  80. Enhancement of Transdermal Protein Delivery by Photothermal Effect of Gold Nanorods Coated on Polysaccharide-based Hydrogel
    A.T. Haine, Y. Koga, Y. Hashimoto, T. Higashi, K. Motoyama, H. Arima, T. Niidome
    Eur. J. Pharm. Biopharm., 119, 91-95 (2017).
  81. Anti-allergic and Profilaggrin (ProFLG)-mRNA expression modulatory effects of sacran
    N.R. Ngatu, K. Motoyama, Y. Nishimura, M.K. Okajima, R. Hirota, T. Higashi, S. Lee, H. Arima, M. Ikeda, S. Nojima, T. Kaneko
    Int. J. Biol. Macromol., 105(Pt 2), 1532-1538 (2017).
  82. Induction of Mitophagy-mediated Antitumor Activity with Folate-appended Methyl-b-cyclodextrin
    K. Kameyama, K. Motoyama, N. Tanaka, Y. Yamashita, T. Higashi, H. Arima
    Int. J. Nanomedicine, 12, 3433-3446(2017).
  83. Ternary complexes of folate-PEG-appended dendrimer (G4)/a-cyclodextrin conjugate, siRNA and low-molecular-weight polysaccharide sacran as a novel tumor-selective siRNA delivery system
    A. Ohyama, T. Higashi, K. Motoyama, H. Arima
    Int. J. Biol. Macromol., 99, 21-28 (2017).
  84. Enhancement of Curcumin Wound Healing Ability by Complexation with 2-Hydroxypropyl-g-cyclodextrin in Sacran Hydrogel Film
    N. Wathoni, K. Motoyama, T. Higashia, M. Okajima, T. Kaneko, H. Arima
    Int. J. Biol. Macromol., 98, 268-276 (2017).
  85. Cyclodextrin-based sustained and controllable release system of insulin utilizing the combination system of self-assembly PEGylation and polypseudorotaxane formation
    T. Hirotsu, T. Higashi, K. Motoyama, H. Arima
    Carbohydr. Polym., 164, 42-48 (2017).
  86. Self-assembly PEGylation Retaining Activity (SPRA) Technology via a Host-guest Interaction Surpassing Conventional PEGylation Methods of Proteins
    T. Hirotsu, T. Higashi, I.I. Abu Hashim, S. Misumi, K. Wada, K. Motoyama, H. Arima
    Mol. Pharm., 14(2), 368-376 (2017).
  87. Stabilizing Effects for Antibody Formulations and Safety Profiles of Cyclodextrin Polypseudorotaxane Hydrogels
    T. Higashi, N. Ohshita, T. Hirotsu, Y. Yamashita, K. Motoyama, S. Koyama, R. IIbuchi, T. Uchida, S. Mieda, K. Handa, T. Kimoto, H. Arima
    J. Pharm. Sci., 106(5), 1266-1274 (2017).
  88. Fabrication of Multi-lactose-appended b-Cyclodextrin and its Cholesterol Lowering Effects in Niemann-Pick Type C Disease-like HepG2 Cells
    K. Motoyama, R. Nishiyama, Y. Maeda, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, T. Era. H. Arima
    Beilstein J. Org. Chem., 13, 10-18 (2017).
  89. Enhancing Effect of g-Cyclodextrin on Wound Dressing Properties of Sacran Hydrogel Film
    N. Wathoni, K. Motoyama, T. Higashi, M. Okajima, T. Kaneko, H. Arima
    Int. J. Biol. Macromol., 94(Pt A), 181-186 (2017).
  90. Cholesterol-lowering Effect of Octaarginine-appended b-Cyclodextrin in Npc1-trap-CHO Cells.
    K. Motoyama, R. Nishiyama, Y. Maeda. T. Higashi, Y. Kawaguchi, S. Futaki, Y. Ishitsuka, Y. Kondo, T. Irie, T. Era, H. Arima
    Biol. Pharm. Bull., 39(11), 1823-1829 (2016).
  91. Ternary inclusion complex formation and stabilization of limaprost, a prostaglandin E1 derivative, in the presence of a- and b-cyclodextrins in the solid state.
    Y. Inoue, D. Iohara, N. Sekiya, M. Yamamoto, H. Ishida, Y. Sakiyama, F. Hirayama, H. Arima, K. Uekama
    Int. J. Pharm., 509(1-2), 338-347 (2016).
  92. Physically Crosslinked-Sacran Hydrogel Films for Wound Dressing Application
    N. Wathoni, K. Motoyama, T. Higashi, M. Okajima, T. Kaneko, H. Arima
    Int. J. Biol. Macromol., 89, 465-470 (2016).
  93. In vitro evaluation of 2-hydroxyalkylated b-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease
    Y. Kondo, H. Tokumaru, Y. Ishitsuka, T. Matsumoto, M. Taguchi, K. Motoyama, T. Higashi, H. Arima, M. Matsuo, K. Higaki, K. Ohno, T. Irie
    Mol. Genet. Metab., 118(3), 214-219 (2016).
  94. Effects of dendrimer/cyclodextrin conjugates as gene transfer carriers on nitric oxide production from macrophages.
    K. Motoyama, A. Sako, I.I. Abu Hashim, T. Higashi, H. Arima
    J. Pharm. Pharmacol., 68(5), 598-607 (2016).
  95. Anti-inflammatory Effects of Novel Polysaccharide Sacran Extracted from Cyanobacterium Aphanothece sacrum in Various Inflammatory Animal Models
    K. Motoyama, Y. Tanida, K. Hata, T. Hayashi, I.I. Abu Hashim, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, S. Kaneko, H. Arima
    Biol. Pharm. Bull., 39(7), 1172-1178 (2016).
  96. Clinical Evaluation of Novel Natural Polysaccharides Sacran as a Skincare Material for Atopic Dermatitis Patients
    S. Fukushima, K. Motoyama, Y. Tanida, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, T. Tanaka, H. Ihn, H. Arima
    J. Cosm. Derm. Sci. Appl., , 6(1), 1-10 (2016).
  97. In Vitro and In Vivo Tumor-targeting siRNA Delivery Using Folate-PEG-appended Dendrimer (G4)/a-Cyclodextrin Conjugates
    A. Ohyama, T. Higashi, K. Motoyama, H. Arima
    Bioconjug. Chem., 27(3), 521-532 (2016).
  98. Thermoresponsive Formation of Dimethyl Cyclodextrin Polypseudorotaxanes and Subsequent One-pot Synthesis of Polyrotaxanes
    T. Higashi, L. Jun, X. Song, J. Zhu, M. Taniyoshi, F. Hirayama, D. Iohara, K. Motoyama, H. Arima
    ACS Macro Lett., 5(2), 158-162 (2016).
  99. Improvement of Pharmaceutical Properties of Isoprenoid Compounds through the Formation of Cyclodextrin Pseudorotaxane-like Supramolecules
    T. Higashi, H. Tanaka, A. Yoshimatsu, H. Ikeda, K. Arima, M. Honjo, C. Iwamoto, K. Motoyama, H. Arima
    Chem. Pharm. Bull., 64(4), 340-345 (2016).
  100. 2-Hydroxypropyl-b-cyclodextrin acts as a novel anticancer agent
    M. Yokoo, Y. Kubota, K. Motoyama, T. Higashi, M. Taniyoshi, H. Tokumaru, R. Nishiyama, Y. Tabe, S. Mochinaga, A. Sato, N. Sueoka-Aragane, E. Sueoka, H. Arima, T. Irie, S. Kimura
    PLos One, 10(11), e0141946 (2015).
  101. Cholesterol Lowering Effects of Mono-lactose-appended b-Cyclodextrin in Niemann-pick Type C Disease-like HepG2 Cells
    K. Motoyama, Y. Hirai, R. Nishiyama, Y. Maeda, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, T. Era, H. Arima
    Beilstein J. Org. Chem., 11, 2079-2086 (2015).
  102. Design and Evaluation of the Highly-concentrated Human IgG Formulation Using Cyclodextrin Polypseudorotaxane Hydrogels
    T. Higashi, A. Tajima, N. Ohshita, T. Hirotsu, I.I. Abu Hashim, K. Motoyama, S. Koyama, R. Iibuchi, S. Mieda, K. Handa, T. Kimoto, H. Arima.
    AAPS PharmSciTech, 16(6), 1290-1298 (2015).
  103. Potential Use of Thioalkylated Mannose-modified Dendrimer (G3)/a-Cyclodextrin Conjugate as a NF-kB siRNA Carrier for the Treatment of Fulminant Hepatitis
    K. Motoyama, R. Mitsuyasu, C. Akao, I.I. Abu Hashim, N. Sato, T. Tanaka, T. Higashi, H. Arima
    Mol. Pharm., 12(9), 3129-3136 (2015).
  104. Inhibition of insulin amyloid fibril formation by cyclodextrins
    K. Kitagawa, Y. Misumi, M. Ueda, Y. Hayashi, M. Tasaki, K. Obayashi, T. Yamashita, H. Jono, H. Arima, Y. Ando
    Amyloid, 22(3), 181-186 (2015).
  105. Effects of Cyclodextrins on GM1-Gangliosides in Fibroblasts from GM1-Gangliosidosis Patients
    Y. Maeda, K. Motoyama, T. Higashi, Y. Horikoshi, T. Takeo, N. Nakagata, Y Kurauchi, H. Katsuki, Y. Ishitsuka, Y. Kondo, T. Irie, H. Furuya, T. Era, H. Arima.
    J. Pharm. Pharmacol., 67(8), 1133-1142 (2015).
  106. Efficacy of 2-hydroxypropyl-b-cyclodextrin in Niemann-Pick disease type C model mice and its pharmacokinetic analysis in a patient with the disease
    Y. Tanaka, Y. Ishitsuka, Y. Yamada, M. Matsuo, K. Shiraishi, K. Wada, Y. Uchio, Y. Kondo, T. Takeo, N. Nakagata, T. Higashi, K. Motoyama, H. Arima, S. Mochinaga, K. Higaki, K. Ohno, T. Irie.
    Biol. Pharm. Bull., 38(6), 844-851 (2015).
  107. Evaluation of Antitumor Effect of Folate-conjugated Methyl-b-cyclodextrin for Melanoma
    K. Motoyama, R. Onodera, N. Tanaka, K. Kameyama, T. Higashi, R. Kariya, S. Okada, H. Arima
    Biol. Pharm. Bull., 38(3), 374-379 (2015).
  108. The antitumor effects of methy-b-cyclodextrin against primary effusion lymphoma via the depletion of cholesterol from lipid rafts
    K. Gotoh, R. Kariya, M. M. Alam, K. Matsuda, S. Hattori, Y. Maeda, K. Motoyama, A. Kojima, H. Arima, S. Okada
    Biochem. Biophys. Res. Commun., 455(3-4), 285-289 (2014).
  109. Preparation and evaluation of cyclodextrin polypseudorotaxane with PEGylated liposome as a sustained release drug carrier
    K. Hayashida, T. Higashi, D. Kono, K. Motoyama, K. Wada, H. Arima
    Beilstein J. Org. Chem., 10, 2756-2764 (2014).
  110. Potential use of fucose-appended dendrimer/a-cyclodextrin conjugates as NF-kB decoy carriers for the treatment of lipopolysaccharide-induced fulminant hepatitis in mice
    C. Akao, T. Tanaka, R. Onodera, A. Ohyama, N. Sato, K. Motoyama, T. Higashi, H. Arima
    J. Control. Release, 193(10), 35-41 (2014).
  111. Design and Evaluation of Thioalkylated Mannose-modified Dendrimer (G3)/a-Cyclodextrin Conjugates as Antigen Presenting Cells-selective siRNA Carriers
    K. Motoyama, R. Mitsuyasu, C. Akao, T. Tanaka, A. Ohyama, N. Sato, T. Higashi, H. Arima
    AAPS J., 16(6), 1298-1308 (2014).
  112. Effects of intrathecal administration of 2-hydroxypropyl-b-cyclodextrin in patients with Niemann-Pick Type C disease
    M. Matsuo, K. Shraishi, K. Wada, Y. Ishitsuka, H. Doi, M. Iimori, T. Mizoguchi, J. Eto, S. Mochinaga, H. Arima, T. Irie
    Mol. Genet. Metab. Rep., 1, 391-400 (2014).
  113. Preparation and evaluation of polyamidoamine dendrimer conjugate with glucuronylglucosyl-b-cyclodextrin (G3) as a novel carrier for siRNA
    A.F. Abdelwahab, A. Ohyama, T. Higashi, K. Motoyama, K.A. Khaled, H.A. Sarhan, A.K. Hussein, H. Arima
    J. Drug Target, 22(10), 927-934 (2014).
  114. Potential use of glucuronylglucosyl-b-cyclodextrin/dendrimer conjugate (G2) as a siRNA carrier for the treatment of familial amyloidotic polyneuropathy
    T. Anno, T. Higashi, Y. Hayashi, K. Motoyama, H. Jono, Y. Ando, H. Arima
    J. Drug Target., 22(10), 883-890 (2014).
  115. Potential Use of a Megamolecular Polysaccharide Sacran as a Hydrogel-based Sustained Release System
    K. Motoyama, Y. Tanida, K. Hata, T. Hayashi, T. Higashi, Y. Ishitsuka, Y. Kondo, T. Irie, S. Kaneko, H. Arima
    Chem. Pharm. Bull., 62(7), 636-641 (2014).
  116. Potential Use of the Complex of Doxorubicin with Folate-conjugated Methyl-b-cyclodextrin for Tumor-selective Cancer Chemotherapy
    K. Motoyama, R. Onodera, A. Okamatsu, T. Higashi, R. Kariya, S. Okada, H. Arima
    J. Drug. Target., 22(3), 211-219 (2014).
  117. Improvement of Pharmaceutical Properties of Insulin through Conjugation with Glucuronylglucosyl-b-cyclodextrin
    T. Hirotsu, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    J. Incl. Phenom. Macro. Chem., 80(1-2), 107-112 (2014).
  118. Involvement of Autophagy in Antitumor Activity of Folate-appended Methyl-b-cyclodextrin
    R. Onodera, K. Motoyama, N. Tanaka, A. Ohyama, A. Okamatsu, T. Higashi, R. Kariya, S. Okada, H. Arima
    Sci. Rep., 4(4417), 1-8 (2014).
  119. Potential Use of Niosomal Hydrogel as an Ocular Delivery System for Atenolol
    I.I. Abu Hashim, M.S. El-dahan, R.M. Yusif, A.-E.H. Abd-ElGawad, H. Arima
    Biol. Pharm. Bull., 37(4), 541-551 (2014).
  120. Influence of Npc1 genotype on the toxicity of hydroxypropyl-b-cyclodextrin, a potentially therapeutic agent, in Niemann-Pick Type C disease models
    Y. Tanaka; Y. Ishitsuka, Y. Yamada; Y. Kondo, T. Takeo, N. Nakagata, T. Higashi, K. Motoyama; H. Arima, M. Matsuo, K. Higaki, K. Ohno, T. Irie
    Mol. Genet. Metab. Rep., 1(1), 19-30 (2014). (2014).
  121. Design and evaluation of folate-appended a-, b- and g-cyclodextrins having a caproic acid as a tumor selective antitumor drug carrier in vitro and in vivo
     A. Okamatsu, K. Motoyama, R. Onodera, T. Higashi, T. Koshigoe, Y. Shimada, K. Hattori, T. Takeuchi, H. Arima
    Biomacromolecules, 14(12), 4420-4428 (2013).
  122. Sugar-appended polyamidoamine dendrimer conjugates with cyclodextrins as cell-specific non-viral vectors
    H. Arima, K. Motoyama, T. Higashi
    Adv. Drug Deliv. Rev., 65(9), 1204-1214 (2013).
  123. Reply: Lung toxicity of hydroxyl-b-cyclodextrin infusion
    M. Matsuo, H. Arima, T. Irie
    Mol. Genet. Metab., 109(2), 233 (2013).
  124. Involvement of Cholesterol Depletion from Lipid Rafts in Apoptosis Induced by Methyl-b-cyclodextrin
    R. Onodera, K. Motoyama, A. Okamatsu, T. Higashi, R. Kariya, S. Okada, H. Arima
    Int. J. Pharm., 452(1-2), 116-123 (2013).
  125. Design and evaluation of polyamidoamine dendrimer conjugate with PEG, a-cyclodextrin and lactose as a novel hepatocyte-selective gene carrier in vitro and in vivo
     Y. Hayashi, T. Higashi, K. Motoyama, Y. Mori, H. Jono, Y. Ando, H. Arima
    J. Drug. Target., 21(5), 487-496 (2013).
  126. Folate-appended b-cyclodextrin as a promising tumor targeting carrier for antitumor drugs in vitro and in vivo
     A. Okamatsu, K. Motoyama, R. Onodera, T. Higashi, T. Koshigoe, Y. Shimada, K. Hattori, T. Takeuchi, H. Arima
    Bioconjug. Chem., 24(4), 724-733 (2013).
  127. Potential Use of Folate-appended Methyl-b-Cyclodextrin as an Anticancer Agent
    R. Onodera, K. Motoyama, A. Okamatsu, T. Higashi, H. Arima
    Sci. Rep., 3, 1104, 1-9 (2013).
  128. Insulin Receptor Activation through Its Accumulation in Lipid Rafts by Mild Electrical Stress
    S. Morino-Koga, S. Yano, T. Kondo, Y. Shimauchi, S. Matsuyama, Y. Okamoto, M.A. Suico, T. Koga, T. Sato, T. Shuto, H. Arima, I. Wada, E. Araki, H. Kai.
    J. Cell. Physiol., 228(2), 439-446 (2013).
  129. Folate-PEG-appended Dendrimer Conjugate with a-Cyclodextrin as a Novel Cancer Cell-selective siRNA Delivery Carrier
    H. Arima, A. Yoshimatsu, H. Ikeda, A. Ohyama, K. Motoyama, T. Higashi, A. Tsuchiya, T. Niidome, Y. Katayama, K. Hattori, T. Takeuchi
    Mol. Pharm., 9(9), 2591-2604 (2012).
  130. Evaluation of photodynamic activity of C(60) /2-hydroxypropyl-b-cyclodextrin nanoparticles
    D. Iohara, M. Hiratsuka, F. Hirayama, K. Takeshita, K. Motoyama, H. Arima, K. Uekama
    J. Pharm. Sci., 101(9), 3390-3397 (2012).
  131. Cyclodextrin/poly(ethylene glycol) Polypseudorotaxane Hydrogels as a Promising Sustained Release System for Lysozyme
    T. Higashi, A. Tajima, K. Motoyama, H. Arima
    J. Pharm. Sci., 101(8), 2891-2899 (2012).
  132. Potential Use of Lactosylated Dendrimer (G3)/ a-cyclodextrin Conjugates as Hepatocyte-specific siRNA Carriers for the Treatment of Familial Amyloidotic Polyneuropathy
    Y. Hayashi, Y. Mori, S. Yamashita, K. Motoyama, T. Higashi, H. Jono, Y. Ando, H. Arima
    Mol. Pharm., 9(6), 1645-1653 (2012).
  133. Potential use of glucuronylglucosyl-b-cyclodextrin as a novel therapeutic tool for familial amyloidotic polyneuropathy
    H. Jono, T. Anno, K. Motoyama, Y. Misumi, M. Tasaki, T. Oshima, Y. Mori, M. Mizuguchi, M. Ueda, S. Shinriki, M. Shono, K. Obayashi, H. Arima, Y. Ando
    Amyloid, 19(S1), 50-52 (2012).
  134. Systemic delivery of transthyretin siRNA mediated by lactosylated dendrimer/a-cyclodextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy therapy
    Y. Hayashi, Y. Mori, T. Higashi, K. Motoyama, H. Jono, D.W. Sah, Y. Ando, H. Arima
    Amyloid, 19(S1), 47-49 (2012).
  135. Potential Use of Folate-polyethylene glycol (PEG)-Appended Dendrimer (G3) Conjugate with a-Cyclodextrin as DNA Carriers to Tumor Cells
    H. Arima, M. Arizono, T. Higashi, A. Yoshimatsu, H. Ikeda, K. Motoyama, K. Hattori, T. Takeuchi, F. Hirayama, K. Uekama
    Cancer Gene Ther., 19(5), 358-366 (2012).
  136. Cyclodextrin-Induced Change in Crystal Habit of Acetylsalicylic Acid in Aqueous Solution
    D. Iohara, K. Yoshida, K. Yamaguchi, M. Anraku, K. Motoyama, H. Arima, K. Uekama, F. Hirayama
    Crystal Growth & Design, 12(4), 1985-1991 (2012).
  137. Possible Enhancing Mechanisms for Gene Transfer Activity of Glucuronylglucosyl-b-cyclodextrin/dendrimer Conjugate (G2)
    T. Anno, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    Int. J. Pharm., 426(1-2), 239-247 (2012).
  138. Polypseudorotaxanes of Pegylated a-Cyclodextrin/Polyamidoamine Dendrimer Conjugate with Cyclodextrins as a Sustained Release System for DNA
    K. Motoyama, K. Hayashida, T. Higashi, H. Arima
    Bioorg. Med. Chem., 20(4), 1425-1433 (2012).
  139. Potential use of glucuronylglucosyl-b-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier in vitro and in vivo
    T. Anno, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    J. Drug Target., 20 (3), 272-280 (2012).
  140. Peak-less Hypoglycemic Effect of Insulin Glargine by Complexation with Maltosyl-b-cyclodextrin. K. Uehata, T. Anno, K. Hayashida, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    Int. J. Pharm., 422(1-2), 33-39 (2012).
  141. Effects of Selected Anionic b-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats
    K. Uehata, T. Anno, K. Hayashida, K. Motoyama, T. Higashi, F. Hirayama, N. Ono , J.D. Pipkin, K. Uekama, H. Arima
    J. Drug Delivery, 2011, 1-9 (2011).
  142. Inhibitory Effect of siRNA Complexes with Polyamidoamine Dendrimer/a-Cyclodextrin Conjugate (Generation 3, G3) on Endogenous Gene Expression
    H. Arima, T. Tsutsumi, A. Yoshimatsu, H. Ikeda, K. Motoyama, T. Higashi, F. Hirayama, K. Uekama
    Eur. J. Pharm. Sci., 44 (3), 375-384 (2011).
  143. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-b-cyclodextrin derivative.
    T. Ishiguro, E. Morishita, D. Iohara, F. Hirayama, K. Wada, K. Motoyama, H. Arima, K. Uekama
    Int. J. Pharm., 419(1-2), 161-169 (2011).
  144. Effect of Sulfobutyl ether-b-cyclodextrin on Bioavailability of Insulin Glargine and Blood Glucose Level after Subcutaneous Injection to Rats
    K. Uehata, T. Anno, K. Hayashida, K. Motoyama, F. Hirayama, N. Ono, J.D. Pipkin, K. Uekama, H. Arima
    Int. J. Pharm., 419(1-2), 71-76 (2011).
  145. Effect of cyclodextrins on Transthyretin amyloid formation in Transthyretin-related amyloidosis
    H. Jono, T. Anno, Y. Misumi, Y. Mori, K. Motoyama, M. Ueda, Y. Horibata, M. Shono, K. Obayashi, H. Arima, Y. Ando
    Amyloid, 18(SUPPL. 1), 58-59 (2011).
  146. Design and Evaluation of Folate-appended Methyl-b-cyclodextrin as a New Antitumor Agent
    R. Onodera, K. Motoyama, H. Arima
    J. Incl. Phenom. Macrocycl. Chem., 70, 321-326 (2011).
  147. In Vitro Gene Delivery Mediated by Lactosylated Dendrimer (generation 3, G3)/a-Cyclodextrin Conjugates into Hepatocytes
    K. Motoyama, Y. Mori, S. Yamashita, Y. Hayashi, H. Jono, Y. Ando, F. Hirayama, K. Uekama, H. Arima
    J. Incl. Phenom. Macrocycl. Chem., 70, 333-338 (2011).
  148. Preparation and Evaluation of Polyamidoamine Dendrimer (G2)/Branched-b-cyclodextrin Conjugate as a Novel Gene Transfer Carrier
    T. Anno, K. Motoyama, T. Higashi, F. Hirayama, K. Uekama, H. Arima
    J. Incl. Phenom. Macrocycl. Chem., 70, 339-344 (2011).
  149. Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis.
    H. Jono, T. Anno, K. Motoyama, Y. Misumi, M. Tasaki, T. Oshima, Y. Mori, M. Mizuguchi, M. Ueda, M. Shono, K. Obayashi, H. Arima, Y. Ando
    Biochem. J., 437(1), 35-42 (2011).
  150. Improvement of Some Physicochemical Properties of Arundic Acid, (R)-(-)-2-Propyloctanonic Acid, by Complexation with Hydrophilic Cyclodextrins.
    Y. Miyamoto, M. Nakahara, K. Motoyama, T. Ishiguro, Y. Oda, T. Yamanoi, I. Okamoto, A. Yagi, H. Nishimura, F. Hirayama, K. Uekama, H. Arima
    Int. J. Pharm., 413(1-2), 63-72 (2011).
  151. Involvement of lipid rafts in macrophage apoptosis induced by cationic liposomes.
    M. Arisaka, K. Takano, Y. Negishi, H. Arima, Y. Aramaki.
    Arch. Biochem. Biophys., 508, 72-77 (2011).
  152. Potential Use of Polypseudorotaxanes of Pegylated Polyamidoamine Dendrimer with Cyclodextrins as Novel Sustained Release Systems for DNA
    K. Motoyama, K. Hayashida, H. Arima
    Chem. Pharm. Bull., 59(4), 476-479 (2011).
  153. Reduction of Bitterness of Antihistaminic Drugs by Complexation with b-Cyclodextrins
    N. Ono (nee Yoshida), Y. Miyamoto, T. Ishiguro, K. Motoyama, F. Hirayama, D. Iohara, H. Seo, S. Tsuruta, H. Arima, K. Uekama
    J. Pharm. Sci., 100(5), 1935-1943 (2011).
  154. In Vitro Gene Delivery Mediated by Asialofetuin-appended Cationic Liposomes Associated with g-Cyclodextrin into Hepatocytes
    K. Motoyama, Y. Nakashima, Y. Aramaki, F. Hirayama, K. Uekama, H. Arima
    J. Drug Delivery, 2011, 1-13 (2011).
  155. In Vitro and In Vivo Gene Delivery Mediated by Lactosylated Dendrimer/a-Cyclodextrin Conjugates (G2) into Hepatocytes.
    H. Arima, S. Yamashita, Y. Mori, Y. Hayashi, K. Motoyama, K. Hattori, T. Takeuchi, H. Jono, Y. Ando, F. Hirayama, K. Uekama
    J. Control. Release, 146(1), 106-117 (2010).
  156. Potential Use of Iontophoresis for Transdermal Delivery of NF-kB Decoy Oligonucleotides.
    I.I. Abu Hashim, K. Motoyama, A.E. Abd-Elgawad, M.H. El-Shabouri, T.M. Borg, H. Arima.
    Int. J. Pharm., 393(1-2), 127-134 (2010).
  157. Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor TELIN
    Y. Kakiuchi, M. Oyama, M. Nakatake, Y. Okamoto, H. Kai, H. Arima, H. Murofushi, K. Murakami-Murofuchi
    Cytologia, 75(2), 177-183 (2010).
  158. Potential use of g-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin.
    I.I. Abu Hashim, T. Higashi, T. Anno, K. Motoyama, A.E. Abd-Elgawad, M.H. El-Shabouri, T.M. Borg, H. Arima.
    Int. J. Pharm., 392(1-2), 83-91 (2010).
  159. Crystallization and Polymorphic Transition of Chlorpropamide in Aqueous 2-Hydroxybutyl-b-cyclodextrin Solution
    T. Ishiguro, F. Hirayama, D. Iohara, H. Arima, K. Uekama
    Eur. J. Pharm. Sci., 39(4), 248-255 (2010).
  160. 5-Fluorouracil acetic acid/b-cyclodextrin conjugates: Drug release behavior in enzymatic and rat cecal media
    K. Udo, K. Hokonohara, K. Motoyama, H. Arima, F. Hirayama, K. Uekama
    Int. J. Pharm., 388(1-2), 95-100 (2010).
  161. A Plasma Protein Indistinguishable from Ribosomal Protein S19: Conversion to a Monocyte Chemotactic Factor by a Factor XIIIa-Catalyzed Reaction on Activated Platelet Membrane Phosphatidylserine in Association with Blood Coagulation
    U. Semba, J. Chen, Y. Ota, N. Jia, H. Arima, H. Nishiura, T. Yamamoto
    Am. J. Pathol., 176(3), 1542-1551 (2010).
  162. Potential Use of 2-Hydroxypropyl-β-cyclodextrin for Preparation of Orally Disintegrating Tablets Containing dl-α-Tocopherol Acetate, an Oily Drug
    K. Motoyama, K. Nagatomo, O.A.E. Soliman, F. Hirayama, K. Uekama, H. Arima
    Chem. Pharm. Bull., 57(11), 1206-1212 (2009).
  163. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-β-cyclodextrin, not 2,6-di-O-methyl-α-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells
    K. Motoyama, K. Kameyama, R. Onodera, N. Araki, F. Hirayama, K. Uekama, H. Arima
    Eur. J. Pharm. Sci., 38(3), 249-261 (2009).
  164. Preparation of Four Types of Coenzyme Q10/g-Cyclodextrin Supramolecular Complexes and Comparison of Their Pharmaceutical Properties
    T. Higashi, K. Nishimura, A. Yoshimatsu, H. Ikeda, K. Arima, K. Motoyama, F. Hirayama, K. Uekama, H. Arima
    Chem. Pharm. Bull., 57(9), 965-970 (2009).
  165. Slow-release System of Pegylated Lysozyme Utilizing Formation of Polypseudorotaxanes with Cyclodextrins.
    T. Higashi, F. Hirayama, S. Yamashita, S. Misumi, H. Arima, K. Uekama
    Int. J. Pharm., 374(1-2), 26-32 (2009).
  166. Polypseudorotaxane Formation of Randomly-pegylated Insulin with Cyclodextrins: Slow Release and Resistance to Enzymatic Degradation.
    T. Higashi, F. Hirayama, S. Misumi, K. Motoyama, H. Arima, K. Uekama
    Chem. Pharm. Bull., 57(5), 541-544 (2009).
  167. Involvement of Lipid Rafts of Rabbit Red Blood Cells in Morphological Changes Induced by Methylated β-Cyclodextrins.
    K. Motoyama, H. Toyodome, R. Onodera, T. Irie, F. Hirayama, K. Uekama, H. Arima
    Biol. Pharm. Bull., 32(4), 700-705 (2009).
  168. Inhibitory Effects of 2,6-Di-O-methyl-a-cyclodextrin on Poly I:C Signaling in Macrophages
    K. Motoyama, Y. Hashimoto, F. Hirayama, K. Uekama, H. Arima
    Eur. J. Pharm. Sci., 36, 285-291 (2009).
  169. Recent Findings of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as DNA and Small-interfering RNA Carriers
    H. Arima, K. Motoyama, F. Hirayama, K. Uekama
    Proc. 14th Int. Cyclodextrins Symposium, 33-41 (2008).
  170. Synthesis and Evaluation of Folate-Modified Cyclodextrins
    K. Hattori, T. Koshigoe, T. Takeuchi, R. Onodera, K. Muraki, H. Akiyama, H. Arima, M. Arizono, K. Uekama
    Proc. 14th Int. Cyclodextrins Symposium, 94-97 (2008).
  171. Folate-PEG-Appended Dendrimer Conjugate with a-Cyclodextrin as a Novel Cancer Cell-Selective Gene Transfer Carrier.
    A. Yoshimatsu, M. Arizono, K. Motoyama, K. Hattori, T. Takeuchi, F. Hirayama, K. Uekama, H. Arima
    Proc. 14th Int. Cyclodextrins Symposium, 276-281 (2008).
  172. Inhibitory Effects of 2,6-di-O-methyl-a-Cyclodextrin on Polyinosinic-Polycytidylic Acid Signaling in Macrophages
    K. Motoyama, Y. Hashimoto, F. Hirayama, K. Uekama, H. Arima
    Proc. 14th Int. Cyclodextrins Symposium, 282-286 (2008).
  173. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system
    T. Higashi, F. Hirayama, S. Misumi, H. Arima, K. Uekama
    Biomaterial, 29, 3866-3871 (2008).
  174. Potential use of Polyamidoamine Dendrimer/a-Cyclodextrin Conjugate (generation 3, G3) as a Novel Carrier for Short Hairpin RNA-Expressing Plasmid DNA
    T. Tsutsumi, F. Hirayama, K. Uekama, H. Arima
    J. Pharm. Sci., 97 (8), 3022-3034 (2008).
  175. Pseudorotaxane-like supramolecular complex of coenzyme Q10 with g-cyclodextrin formed by solubility method
    K. Nishimura, T. Higashi, A. Yoshimatsu, F. Hirayama, K. Uekama, H. Arima.
    Chem. Pharm. Bull., 56(5), 701-706 (2008).
  176. Preparation of amorphous indomethacin from aqueous 2,6-di-O-methyl-b-cyclodextrin solution
    D. Iohara, F. Hirayama, T. Ishiguro, H. Arima, K. Uekama.
    Int. J. Pharm., 354(1-2), 70-76 (2008).
  177. Methyl-b-Cyclodextrin Improves Fertilizing Ability of C57BL/6 Mouse Sperm after Freezing and Thawing by Facilitating Cholesterol Efflux from the Cells.
    T. Takeo, T. Hoshii, Y. Kondo, H. Toyodome, H. Arima, K.I. Yamamura, T. Irie, N. Nakagata.
    Biol. Reprod., 78(3), 546-551 (2008).
  178. Improved Stability of OPALMON Tablets under Humid Conditions IV: Effect of polysaccharides and disintegrants on the stability and dissolution property of OPALMON Tablets
    N. Sekiya, A. Nishiwaki, A. Nishiura, M. Yamamoto, K. Takeda, D. Iohara, F. Hirayama, H. Arima, K. Uekama
    Chem. Pharm. Bull., 56(1), 7-11 (2008).
  179. Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with b-cyclodextrin
    K. Anzai, J. Mizoguchi, T. Yanagi, F. Hirayama, H. Arima, K. Uekama
    Chem. Pharm. Bull. , 55(10), 1466-1470 (2007).
  180. Evaluation of polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA)
    T. Tsutsumi, F. Hirayama, K. Uekama, H. Arima
    J. Control. Release, 119(3), 349-359 (2007).
  181. Polypseudorotaxanes of pegylated insulin with cyclodextrins: Application to sustained release system
    T. Higashi, F. Hirayama, H. Arima, K. Uekama
    Bioorg. Med. Chem. Lett., 17(7), 1871-1874 (2007).
  182. Enhancement of gene transfer activity mediated by mannosylated dendrimer/α-cyclodextrin conjugate (generation 3, G3)
    H. Arima, Y. Chihara, M. Arizono, S. Yamashita, K. Wada, F. Hirayama, K. Uekama
    J. Control. Release, 116(1), 64-74 (2006).
  183. Effects of Cyclodextrins on Chemically- and Thermally-induced Unfolding and Aggregation of Lysozyme and Basic Fibroblast Growth Factor
    S. Tavornvipas, F. Hirayama, S. Takeda, H. Arima, K. Uekama
    J. Pharm. Sci. , 95(12), 2722-2729 (2006). abstract
  184. Enhancement of oral bioavailability of coenzyme Q10 by the complexation with γ-cyclodextrin in healthyl adult volunteers
    K. Terao, D. Nakata, H. Fukumi, G. Schmid, H. Arima, F. Hirayama, K. Uekama
    Nutr. Res. , 26, 503-508 (2006). abstract
  185. Effect of 2,6-Di-O-methyl-α-cyclodextrin on Hemolysis and Morphological Change in Rabbit's Red Blood Cells
    K. Motoyama, H. Arima, H. Toyodome, T. Irie, F. Hirayama, K. Uekama
    Eur. J. Pharm. Sci. , 29(2), 111-119 (2006). abstract
  186. Enhanced Bioavailability of a New Thiazolidine Derivative FPFS-410, an Antidiabetic and Lipid-lowering Drug, after Oral Administration of Its Hydroxypropyl-β-cyclodextrin Complex to Bile Duct-cannulated Rats
    T. Hara, H. Arima, F. Hirayama, K. Uekama
    J. Pharm. Sci. , 95(8), 1771-1782 (2006). abstract
  187. Enhancement of Antitumor Effect of Doxorubicin by Its Complexation with γ-Cyclodextrin in Pegylated Liposomes
    H. Arima, Y. Hagiwara, F. Hirayama, K. Uekama
    J. Drug Target. , 14(4), 225-232 (2006). abstract
  188. Selective Crystallization of Metastable Form IV Polymorph of Tolbutamide in the Presence of 2,6-Di-O-methyl-β-cyclodextrin in Aqueous Solution
    Y. Sonoda, F. Hirayama, H. Arima, Y. Yamaguchi, W. Saenger, K. Uekama
    Crystal Growth & Design , 6, 1181-1185 (2006). abstract
  189. Enhanced Dissolution and Oral Bioavailability of Coenzyme Q10 in Dogs by Inclusion Complexation with γ-Cyclodextrin
    X.Y. Gao, K. Nishimura, F. Hirayama, H. Arima, K. Uekama, G. Schmid, K. Terao, D. Nakata, H. Fukumi
    Asian J. Pharm. Sci. ,1(2), 95-102 (2006).
  190. Cyclodextrin-based isolation of Ostwald's metastable polymorphs occurring during crystallization.
    Y. Sonoda, F. Hirayama, H. Arima, Y. Yamaguchi, W. Saenger, K. Uekama
    Chem. Commun., (5), 517-519 (2006). abstract
  191. Two-dimensional (13)C-(1)H heteronuclear correlation NMR spectroscopic studies for the inclusion complex of cyclomaltoheptaose (β-cyclodextrin) with a new Helicobacter pylori eradicating agent (TG44) in the amorphous state.
    K. Anzai, H. Kono, J.I. Mizoguchi, T. Yanagi, F. Hirayama, H. Arima, K. Uekama
    Carbohydr. Res., 341(4), 499-506 (2006). abstract
  192. Preparation and Pharmaceutical Evaluation of Liposomes Entrapping Salicylic Acid/γ-Cyclodextrin Conjugate
    Y. Hagiwara, H. Arima, Y. Miyamoto, F. Hirayama, K. Uekama
    Chem. Pharm. Bull., 54(1), 26-32 (2006). abstract
  193. Improvement of Solubility and Oral Bioavailability of 2-(N-Cyanoimino)-5-{(E)-4-styrylbenzylidene}-4- oxothiazolidine (FPFS-410) with Antidiabetic and Lipid-lowering Activities in Dogs by 2-Hydroxypropyl-β-cyclodextrin
    T. Hara, F. Hirayama, H. Arima, Y. Yamaguchi, K. Uekama
    Chem. Pharm. Bull., 54(3), 344-349 (2006). abstract
  194. Prolonged Retention of Doxorubicin in Tumor Cells by Encapsulation of γ-Cyclodextrin Complex in Pegylated Liposomes
    Y. Hagiwara, H. Arima, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 65-68 (2006).
  195. Prominent Solubilizing Effect of 2-Hydoxypropyl-β-cyclodextrin on a New Thiazolidine Derivative (FPFS-410) with Antidiabetic and Lipid-lowering Activities through Inclusion Complex Formation
    T. Hara, F. Hirayama, H. Arima, Y. Yamaguchi, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 135-139 (2006).
  196. Improvement of Dispersion and Release Properties of Nifedipine in Suppositories by Complexation with 2-Hydroxypropyl-β-cyclodextrin
    K. Nishimura, R. Hidaka, F. Hirayama, H. Arima, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 85-88 (2006).
  197. Inhibitory Effects of 2,6-Di-O-methyl-3-O-acetyl-β-cyclodextrins with Various Degrees of Substitution of Acetyl Group on Macrophage Activation and Endotoxin Shock Induced by Lipopolysaccharide.
    K. Motoyama, H. Arima, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 75-79 (2006).
  198. Serum-resistant Gene Transfer Activity of Mannosylated Dendrimer/α-Cyclodextrin Conjugate (G3)
    Y. Chihara, H. Arima, M. Arizono, K. Wada, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 89-93 (2006).
  199. Potential Use of Dendrimer/α-Cyclodextrin Conjugate as a Novel Carrier for Small Interfering RNA (siRNA)
    T. Tsutsumi, H. Arima, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 56, 81-84 (2006).
  200. Membrane-anchored CD14 is required for LPS-induced TLR4 endocytosis in TLR4/MD-2/CD14 overexpressing CHO cells
    T. Shuto, K. Kato, Y. Mori, S. Viriyakosol, M. Oba, T. Furuta, T. Okiyoneda, H. Arima, M.A. Suico, H. Kai
    Biochem. Biophys. Res. Commun., 338, 1402-1409 (2005). abstract
  201. Inhibitory effects of dimethylacetyl-β-cyclodextrin on lipopolysaccharide-induced macrophage activation and endotoxin shock in mice
    H. Arima, K. Motoyama, A. Matsukawa, Y. Nishimoto, F. Hirayama, K. Uekama
    Biochem. Pharmacol.,70(10), 1506-1517 (2005). abstract
  202. Improvement of gene delivery mediated by mannosylated dendrimer/α-cyclodextrin conjugates
    K. Wada, H. Arima, T. Tsutsumi, Y. Chihara, K. Hattori, F. Hirayama, K. Uekama
    J. Control. Rel.,104(2), 397-414 (2005). abstract
  203. Involvement of CD14 in the inhibitory effects of dimethyl-α-cyclodextrin on lipopolysaccharide signaling in macrophages
    K. Motoyama, H. Arima, Y. Nishimoto, K. Miyake, F. Hirayama, K. Uekama
    FEBS Lett., 579(7), 1707-1714 (2005). abstract
  204. Enhancing Effects of Galactosylated Dendrimer/α-Cyclodextrin Conjugates on Gene Transfer Efficiency
    K. Wada, H. Arima, T. Tsutsumi, F. Hirayama, K. Uekama
    Biol. Pharm. Bull., 28(3), 500-505 (2005). abstract
  205. Pharmaceutical Application of Cyclodextrins as Multi-functional Drug Carrier
    K. Uekama
    Yakugaku Zasshi, 124(12), 909-935 (2004). abstract
  206. Effects of Hydrophilic Cyclodextrins on Aggregation of Recombinant Human Growth Hormone
    S. Tavornvipas, S. Tajiri, F. Hirayama, H. Arima, K. Uekama
    Pharm. Res., 21 2369-2376 (2004). abstract
  207. Applicability of (SBE)(7m)-β-CD in controlled-porosity osmotic pump tablets (OPTs).
    K. Okimoto, Y. Tokunaga, R. Ibuki, T. Irie, K. Uekama, R.A. Rajewski, V.J. Stella
    Int. J. Pharm., 286 (1-2) 81-88 (2004). abstract
  208. Effects of 2-Hydroxypropyl-β-cyclodextrin on Polymorphic Transition of Chlorpropamide in Various Conditions: Temperature, Humidity and Moulding Pressure.
    Y. Sonoda, F. Hirayama, H. Arima, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem., 50 (4) 73-77 (2004). abstract
  209. Design and evaluation of cyclodextrin-based drug formulation.
    K. Uekama
    Chem. Pharm. Bull., 52(8), 900-915 (2004). abstract
  210. Polyfection as Nonviral Gene Transfer Method -Design of Novel Nonviral Vector Using α-Cyclodextrin-.
    H. Arima
    Yakugaku Zasshi, 124(7), 451-464 (2004). abstract
  211. NMR Spectroscopic Characterization of Metoprolol/Cyclodextrin Complexes in Aqueous Solution: Cavity Size Dependency.
    Y. Ikeda, F. Hirayama, H. Arima, K. Uekama, Y. Yoshitake, K. Harano
    J. Pharm. Sci., 93(7), 1659-1671 (2004). abstract
  212. Potential Use of 2-Hydroxypropyl-β-cyclodextrin as a Release Modifier of a Water-soluble Drug, Metoprolol Tartrate, from Ethylcellulose Tablets.
    Y. Ikeda, S. Motoune, M. Ono, H. Arima, F. Hirayama, K. Uekama
    J. Drug Del. Sci. Tech., 14(1), 69-76 (2004). abstract
  213. Contribution of Cholesterol and Phospholipids to Inhibitory Effect of Dimethyl-β-cyclodextrin on Efflux Function of P-glycoprotein and Multidrug Resistance-associated Protein 2 (MRP2) in Vinblastine-resistant Caco-2 Cell Monolayers.
    H. Arima, K. Yunomae, T. Morikawa, F. Hirayama, K. Uekama
    Pharm. Res., 21(4), 625-634 (2004). abstract
  214. Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin-10 in NC/Nga mice.
    T. Sakamoto, E. Miyazaki, Y. Aramaki, H. Arima, M. Takahashi, Y. Kato, M. Koga, S. Tsuchiya
    Gene Ther., 11(3), 317-324 (2004). abstract
  215. In Vitro and In Vivo Gene Transfer by an Optimized α-Cyclodextrin Conjugate with Polyamidoamine Dendrimer.
    F. Kihara, H. Arima, T. Tsutsumi, F. Hirayama, K. Uekama
    Bioconjugate Chem, 14(2), 342-350 (2003). abstract
  216. Involvement of cholesterol in the inhibitory effect of dimethyl-β-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells.
    K. Yunomae, H. Arima, F. Hirayama, K. Uekama
    FEBS Lett., 536(1-3), 225-231 (2003) . abstract
  217. Efficient Gene Transfer to Hepatoblastoma Cells through Asialoglycoprotein Receptor and Expression under the Control of the Cyclin A Promoter.
    Y. Aramaki, I. Lee, H. Arima, T. Sakamoto, Y. Magami,T. Yoshimoto, F. Moriyasu, J. Mizuguchi, Y. Koyanagi, T. Nikaido, S. Tsuchiya.
    Biol. Pharm. Bull., 26(3), 357-360 (2003). abstract
  218. Inhibitory Effect of Sulfobutyl Ether β-Cyclodextrin on DY-9760e-Induced Cellular Damage: In Vitro and In Vivo Studies.
    Y. Nagase, H. Arima, K. Wada, T. Sugawara, H. Satoh, F. Hirayama, K. Uekama.
    J. Pharm. Sci., 92(12), 2475-2483 (2003). abstract
  219. Intradermal Delivery of Antisense Oligonucleotides by the Pulse Depolarization Iontophoretic System.
    Y. Aramaki, H. Arima, M. Takahashi, E. Miyazaki, T. Sakamoto, S. Tsuchiya
    Biol. Pharm. Bull., 26(10), 1461-1466 (2003). abstract
  220. Recent Aspects of Pharmaceutical Application of Cyclodextrins.
    K. Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 3-7 (2002). abstract
  221. Model Analysis for Oral Absorption of a Drug/Cyclodextrin Complex Involving Competitive Inclusion Complexes.
    N. Ono, F. Hirayama, H. Arima, K. Uekama, J.H. Rytting
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 93-96 (2002). abstract
  222. Inclusion Complexation of a Seleno-Organic Antioxidant, Ebselen, with Cyclodextrins in Aqueous Solution.
    Y. Nagase, N. Suzuki, H. Yamauchi, S. Kim, K. Wada, H. Arima, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 107-110 (2002). abstract
  223. Effect of 2-Hydroxypropyl-β-cyclodextrin on Release Rate of Metoprolol from Ternary Metoprolol/2-hydroxypropyl-β-cyclodextrin/Ethylcellulose Tablets.
    Y. Ikeda, S. Motoune, A. Marumoto, Y. Sonoda, F. Hirayama, H. Arima, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 141-144 (2002). abstract
  224. Prolonged Plasma Levels of Ketoprofen after Oral Administration of Its α-Cyclodextrin Conjugate/Ethylcellulose Dispersion in Rats .
    F. Hirayama, M. Kamada, H. Yano, K. Udo, H. Arima, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 159-161 (2002). abstract
  225. Cell-Specific Gene Transfer by α-Cyclodextrin Conjugates with Mannosylated Polyamidoamine.
    H. Arima, K. Wada, F. Kihara, T. Tsutsumi, F. Hirayama, K. Uekama
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 361-364 (2002). abstract
  226. Some Pharmaceutical Properties of a New Branched Cyclodextrin, 6- O-α-(4- O- α-D-Glucuronyl)-D-glucosyl β-cyclodextrin.
    S. Tavornvipas, H. Arima, F. Hirayama, K. Uekama, T. Ishiguro, M. Oka, K. Hamayasu, H. Hashimoto
    J. Incl. Phenom. Macrocycl. Chem. , 44(2), 391-394 (2002). abstract
  227. Protective effect of sulfobutyl ether β-cyclodextrin on DY-9760e-induced hemolysis in vitro
    Y. Nagase, M. Hirata, H. Arima, S. Tajiri, Y. Nishimoto, F. Hirayama, T. Irie, K. Uekama:
    J. Pharm Sci., 91, 2382-2389 (2002). abstract
  228. Effects of Structure of Polyamidoamine Dendrimer on Gene Transfer Efficiency of the Dendrimer Conjugate with α-Cyclodextrin.
    F. Kihara, H. Arima, T. Tsutsumi, F. Hirayama, K. Uekama
    Bioconjugate Chem., 13, 211-1219 (2002). abstract
  229. 6-O-α-(4-O-α-D-glucuronyl)-D-glucosyl-β-cyclodextrin: solubilizing ability and some cellular effects.
    S. Tavornvipas, F. Hirayama, H. Arima, K. Uekama, T. Ishiguro, M. Oka, K. Hamayasu, H. Hashimoto
    Int. J. Pharm., 249, 199-209 (2002). abstract
  230. Inclusion complex formation of captopril with α- and β-cyclodextrins in aqueous solution: NMR spectroscopic and molecular dynamic studies.
    Y. Ikeda, S. Motoune, T. Matsuoka, H. Arima, F. Hirayama, K. Uekama
    J. Pharm. Sci., 91, 2390-2398 (2002). abstract
  231. Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats
    M. Kamada, F. Hirayama, K. Udo, H. Yano, H. Arima, K. Uekama:
    J. Control. Rel., 82, 407-416 (2002). abstract
  232. Colon-specific delivery of prednisolone-appended α-cyclodextrin conjugate: alleviation of systemic side effect after oral administration
    H. Yano, F. Hirayama, M. Kamada, H. Arima, K. Uekama:
    J. Control. Rel., 79, 103-112 (2002). abstract
  233. Enhancement of Gene Expression by Polyamidoamine Dendrimer Conjugates with α-, β-, γ-Cyclodextrins.
    H. Arima, F. Kihara, F. Hirayama, K. Uekama:
    Bioconjugate Chem., 12, 476-484 (2001). abstract
  234. A Moderate Interaction of Maltosyl-α-cyclodextrin with Caco-2 Cells in Comparison with the Parent Cyclodextrin.
    N. Ono, H. Arima, F. Hirayama, K. Uekama:
    Biol. Pharm. Bull., 24,395-402 (2001). abstract
  235. Transparent, Adhesive Film Formation of Per-O-valeryl-β-cyclodextrin.
    F. Hirayama, K. Zaoh, K. Harata, W. Saenger, K. Uekama:
    Chem. Lett., 636-637 (2001). abstract
  236. Analysis of Phase Solubility Diagram of Phenacetin/Competitor/β-Cyclodextrin Ternary System, Involving Competitive Inclusion Complexation.
    N. Ono, F. Hirayama, H. Arima, K. Uekama
    Chem. Pharm. Bull., 49,78-81 (2001). abstract
  237. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether β-cyclodextrin
    Y. Nagase, M. Hirata, K. Wada, H. Arima, F. Hirayama, T. Irie, M. Kikuchi, K. Uekama
    Int. J. Pharm., 229, 163-172 (2001). abstract
  238. Effect of Peracylation of β-Cyclodextrin on the Molecular Structure and on the Formation of Inclision Complexes: An X-Ray Study:
    M. Anibarro, K. Gessler, I. Uson, G. M. Sheldrick, K. Harata, K. Uekama, F. Hirayama, Y. Abe, W. Saenger:
    J. Am. Chem. Soc., 123, 11854-11862 (2001) abstract
  239. Contribution of P-glycoprotein to Enhancing Effects of Dimethyl-β-cyclodextrin on Oral Bioavailability of Tacrolimus.
    H. Arima, K. Yunomae, F. Hirayama, K. Uekama:
    J. Pharmacol. Exp. Ther., 297, 547-555 (2001). abstract
  240. Preparation of Prednisolone-appended α-, β-, and γ-Cyclodextrins: Substitution at Secondary Hydroxyl Groups and In Vitro Hydrolysis Behavior.
    H. Yano, F. Hirayama, H. Arima, K. Uekama:
    J. Pharm. Sci., 90, 493-503 (2001). abstract
  241. Comparative Studies of the Enhancing Effects of Cyclodextrins on the Solubility and Oral Bioavailability of Tacrolimus in Rats.
    H. Arima, K. Yunomae, K. Miyake, T. Irie, F. Hirayama, K. Uekama:
    J. Pharm. Sci., 90, 690-701 (2001). abstract
  242. Prednisolone-appended α-Cyclodextrin: Alleviation of Systemic Adverse Effect of Prednisolone after Intracolonic Administration in 2,4,6-Trinitrobenzenesulfonic Acid Induced Colitis Rats.
    H. Yano, F. Hirayama, H. Arima, K. Uekama:
    J. Pharm. Sci., 90, 2103-2112 (2001). abstract
  243. Inhibitory Effects of Novel Hydrophilic Cyclodextrin Derivatives on Nitric Oxide Production in Macropharges Stimulated with Lipopolysaccharide.
    H. Arima, Y. Nishimoto, K. Motoyama, F. Hirayama, K. Uekama:
    Pharm. Res., 18(8), 1167-1173 (2001). abstract
  244. Stabilizing and Solubilizing Effects of Sulphobutyl Ether β-Cyclodextrin (SBE-β-CyD) on Prostaglandin E 1 Analogue.
    K. Uekama, Y. Hieda, F. Hirayama, H. Arima, M. Sudoh, A. Yagi, H. Terashima:
    Pharm. Res., 18,1578-1585 (2001). abstract
  245. Crystal Structures of Heptakis(2,6-di-O-ethyl)cyclomaltoheptaose [Heptakis(2,6-di-O- ethyl)-β-cyclodextrin]. Solvent-regulated Helical Assembly of Macrocycles.
    K. Harata, F. Hirayama, and K. Uekama:
    Carbohydr. Res., 329, 597-607 (2000).
  246. Effects of Ageing on Crystallization, Dissolution and Absorption Characteristics of Amorphous Tolbutamide/2-Hydroxypropyl-β-cyclodextrin Complex.
    K. Kimura, F. Hirayama, H. Arima, K. Uekama:
    Chem. Pharm. Bull., 48, 646-650 (2000).
  247. Hydrolysis Behavior of Prednisolone 21-Succinate/β-Cyclodextrin Amide Conjugate: Involvement of Intramolecular Catalysis of Amide Group in Drug Release.
    H. Yano, F. Hirayama, H. Arima, K. Uekama:
    Chem. Pharm. Bull., 48, 1125-1128 (2000).
  248. Inclusion Complex of 3,9-Bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c] quinoline- 6-one (KCA-098) with Heptakis(2,6-di-O-methyl)-β-cyclodextrin: Interaction and Dissolution Properties.
    T. Yamada, T. Imai, K. Ohuchi, M. Otagiri, F. Hirayama, K. Uekama:
    Chem. Pharm. Bull., 48, 1264-1269 (2000).
  249. X-ray Crystallographic Characterization of Nilvadipine Monohydrate and Its Phase Transition Behavior.
    F. Hirayama, M. Honjo, H. Arima, K. Okimoto, K. Uekama:
    Eur. J. Pharm. Sci., 11, 81-88 (2000).
  250. Controlled Release of a Water-soluble Drug, Captopril, by a Combination of Hydrophilic and Hydrophobic Cyclodextrin Derivatives.
    Y. Ikeda, K. Kimura, F. Hirayama, H. Arima, K. Uekama:
    J. Control. Rel., 66, 271-280 (2000).
  251. Improvement in Some Physicochemical and Biological Properties of LG106W by Inclusion Complexation with β-Cyclodextrin and Its Derivatives.
    S.H. Jeong, C.K. Lee, W.G. Cho, S.H. Kang, K. Uekama:
    J. Cosmet. Sci., 51, 227-237 (2000).
  252. Improvements of Subcutaneous Bioavailability of Insulin by Sulfobutyl Ether β- Cyclodextrin in Rats.
    K. Tokihiro, H. Arima, S. Tajiri, T. Irie, F. Hirayama, K. Uekama,
    J. Pharm. Pharmacol., 52, 911-917 (2000).
  253. Release Characteristics of a Short-chain Fatty Acid, n-Butylic Acid, from Its β-Cyclodextrin Ester Conjugates in Rat Biological Media.
    F. Hirayama, T. Ogata, H. Yano, H. Arima, K. Udo, M. Takano, K. Uekama:
    J. Pharm. Sci., 89, 1486-1495 (2000).
  254. Improvement of Solubility and Oral Bioavailability of Rutin by Complexation with 2-Hydroxypropyl-β-cyclodextrin.
    K. Miyake, H. Arima, F. Hirayama, M. Yamamoto, T. Horikawa, H. Sumiyoshi, S. Noda, K. Uekama:
    Pharm. Devel. Tech., 5, 399-407 (2000).
  255. Enhanced Absorption of Cyclosporin A by Complexation with Dimethyl-β-cyclodextrin in Bile Duct-Cannulated and -Noncannulated Rats.
    K. Miyake, H. Arima, T. Irie, F. Hirayama, K. Uekama:
    Biol. Pharm. Bull., 22, 66-72 (1999).
  256. Inhibitory Effect of 2-Hydroxypropyl-β-cyclodextrin on the Foaming Generated by the Phosphodiester Compound of Vitamin C and E, EPC-K1.
    Y. Hamano, K. Ito, H. Matsuda, H. Arima, H. Sumiyoshi, F. Hirayama, K. Uekama:
    Chem. Pharm. Bull., 47, 828-832 (1999).
  257. Release-control of a Water-soluble Drug by Film-forming Trivaleryl-β-cyclodextrin.
    M. Yamada, F. Hirayama, K. Uekama:
    Drug Delivery System, 14, 27-32 (1999).
  258. Determination of Stability Constant of β-Cyclodextrin Complexes by Membrane Permeation Technique and Permeation Behavior of Drug/Competing Agent/β-Cyclodextrin Ternary System.
    N. Ono, F. Hirayama, H. Arima, K. Uekama:
    Eur. J. Pharm. Sci., 88, 133-139 (1999).
  259. Characterization of Itraconazole/2-Hydroxypropyl-β-cyclodextrin Inclusion Complex in Aqueous Propylene Glycol Solution.
    K. Miyake, T. Irie, H. Arima, F. Hirayama, K. Uekama, M. Hirano, Y. Okamoto:
    Int. J. Pharm., 179, 237-245 (1999).
  260. Factors Affecting Membrane Controlled Drug Release for an Osmotic Pump Tablet (OPT) Utilizing (SBE)7m-β-Cyclodextrin as both a Solubilizer and Osmotic Agent.
    K. Okimoto, A. Ohike, R. Ibuki, N. Ohnishi, R.A. Rajewski, V.J. Stella, T. Irie, K. Uekama:
    J. Control. Rel., 60, 311-319 (1999).
  261. Solubility and Mass and Nuclear Magnetic Resonance Spectroscopic Studies on Interaction of Cyclosporin A with Dimethyl-α- and β-Cyclodextrins in Aqueous Solution.
    K. Miyake, F. Hirayama, K. Uekama:
    J. Pharm. Sci., 88, 39-45 (1999).
  262. Characterization of Tolbutamide Polymorphs (Burger's Forms II and IV) and Polymorphic Polymorphic Transition Behavior.
    K. Kimura, F. Hirayama, K. Uekama:
    J. Pharm. Sci., 88, 385-391 (1999).
  263. Heptakis(2,6-di-O-methyl-3-O-acetyl)-β-cyclodextrin: A Water-soluble Cyclodextrin Derivative with Low Hemolytic Activity.
    F. Hirayama, S. Mieda, Y. Miyamoto, H. Arima, K. Uekama:
    J. Pharm. Sci., 88, 970-975 (1999).
  264. Solid-state 13C Nuclear Magnetic Resonance Spectroscopic Study on Amorphous Solid Complexes of Tolbutamide with 2-Hydroxypropyl-α and β-Cyclodextrins.
    K. Kimura, F. Hirayama, H. Arima, K. Uekama:
    Pharm. Res., 16, 1729-1734 (1999).
  265. Design and Evaluation of an Osmotic Pump Tablet (OPT) for Chlorpromazine Using (SBE)7m-β-cyclodextrin.
    K. Okimoto, A. Ohike, R. Ibuki, N. Ohnishi, R.A. Rajewski, V.J. Stella, T. Irie, K. Uekama:
    Pharm. Res., 16, 549-554 (1999).
  266. Homogeneous Assay for Measuring Low-Density Lipoprotein Cholesterol in Serum with Triblock Copolymer and α-Cyclodextrin Sulfate.
    H. Sugiuchi, T. Irie, Y. Uji, T. Ueno, T. Chaen, K. Uekama, H. Okabe:
    Clin. Chem., 44, 522-531 (1998).
  267. Improvements of Gastrointestinal Absorption and Lymphatic Transfer of Cyclosporin A by Various Cyclodextrins.
    K. Miyake, T. Irie, F. Hirayama, K. Uekama:
    Drug Delivery System, 13, 369-375 (1998).
  268. Enhancing Effect of Hydroxypropyl-β-cyclodextrin on Cutaneous Penetration and Activation of Ethyl 4-Biphenylyl Acetate in Hairless Mouse Skin.
    H. Arima, T. Miyaji, T. Irie, F. Hirayama, K. Uekama:
    Eur. J. Pharm. Sci., 6, 53-59 (1998).
  269. Colon-specific Drug Delivery Based on a Cyclodextrin Prodrug: Release Behavior of Biphenylylacetic Acid from Its Cyclodextrin Conjugates in Rat Intestinal Tracts after Oral Administration.
    K. Minami, F. Hirayama, K. Uekama:
    J. Pharm. Sci., 87, 715-720 (1998).
  270. Design and Evaluation of an Osmotic Pump Tablet (OPT) for Prednisolone, a Poorly Water-soluble Drug, Using (SBE)7m-β-Cyclodextrin.
    K. Okimoto, M. Miyake, N. Ohnishi, R.A. Rajewski, V.J. Stella, T. Irie, K. Uekama:
    Pharm. Res., 15, 1562-1568 (1998).
  271. Spectroscopic Characterization of Inclusion Complex of a Luteinizing Hormone- Releasing Hormone Agonist, Buserelin Acetate, with Dimethyl-β-cyclodextrin.
    K. Matsubara, T. Irie, K. Uekama:
    Chem. Pharm. Bull., 45, 378-383 (1997).
  272. Varing Effects of Cyclodextrin Derivatives on Aggregation and Thermal Behavior of Insulin in Aqueous Solution.
    K. Tokihiro, T. Irie, K. Uekama:
    Chem. Pharm. Bull., 45, 525-531 (1997).
  273. Crystallization and Polymorphic Transition Behavior of Chloramphenicol Palmitate in 2-Hydroxypropyl-β-cyclodextrin Matrix.
    F. Hirayama, M. Usami, K. Kimura, K. Uekama:
    Eur. J. Pharm. Sci., 5, 23-30 (1997).
  274. Amorphous Spironolactone-Hydroxypropylated Cyclodextrins with Superior Dissolution and Oral Bioavailability.
    O.A. Soliman, K. Kimura, F. Hirayama, K. Uekama, H.M. El-Sabbagh, A.H. Abd El-Gawad, F.M. Hashim:
    Int. J. Pharm., 149, 73-83 (1997).
  275. Application of a β-Cyclodextrin Sulfate-immobilized Precolumn to Selective On-line Enrichment and Separation of Heparin-binding Proteins by Column-switching High performance Liquid Chromatography.
    K. Ishimaru, K. Fukunaga, T. Irie, K. Uekama, T. Ohta, H. Nakamura:
    J. Chromatogr. A, 769, 209-214 (1997).
  276. 6A-O-[(4-Biphenylyl)-acetyl]-α-, β- and γ-cyclodextrins and 6A-Deoxy-6A-amino [(4- biphenylyl)-acetyl]-α-, β-, and γ-cyclodextrins: Potential Prodrugs for Colon-Specific Delivery.
    K. Uekama, K. Minami, F. Hirayama:
    J. Med. Chem., 40, 2755-2761 (1997).
  277. Protection Afforded by Maltosyl-β-cyclodextrin against α-Chymotrypsin-catalyzed Hydrolysis of a Luteinizing Hormone-releasing Hormone Agonist, Buserelin Acetate.
    K. Matsubara, Y. Ando, T. Irie, K. Uekama:
    Pharm. Res., 14, 1401-1405 (1997).
  278. Combination Effects of α-Cyclodextrin and Xanthan Gum on Rectal Absorption and Metabolism of Morphine from Hollow-Type Suppositories in Rabbits.
    T. Kondo, T. Irie, K. Uekama:
    Biol. Pharm. Bull., 19, 280-286 (1996).
  279. Crystal Structures of Hexakis-(2,6-di-O-methyl)cyclomaltohexaose (Dimethyl-α-cyclodextrin) Crystallized from Acetone, and Crystallized from Hot Water.
    T. Steiner, F. Hirayama, W. Saenger:
    Carbohydr. Res., 296, 69-82 (1996).
  280. 2-Hydroxypropylated Cyclodextrins as Sustained-release Carrier for Fragrance Materials.
    M. Tanaka, H. Matsuda,H. Sumiyoshi, H. Arima, F. Hirayama, K. Uekama, S. Tsuchiya:
    Chem. Pharm. Bull., 44, 416-420 (1996).
  281. Possible Enhancing Mechanism of Cutaneous Permeation of 4-Biphenylylacetic Acid by β-Cyclodextrin Derivatives in Hydrophilic Ointment.
    H. Arima, T. Miyaji, T. Irie, F. Hirayama, K. Uekama:
    Chem. Pharm. Bull., 44, 582-586 (1996).
  282. Effects of Cyclodextrin Derivatives on Systemic Absorption of Morphine through Nasal Cavity and Entry into Central Nervous System.
    T. Kondo, T. Irie, K. Uekama:
    Drug Delivery System, 11, 99-104 (1996).
  283. Controlled Transdermal Delivery of Beraprost, a Prostaglandin I 2 Analogue, by Conbined Use of Fatty Acid and Cyclodextrins.
    Y. Ogata, H. Adachi, T. Irie, K. Uekama:
    Drug Delivery System, 11, 435-440 (1996).
  284. In-Vitro Evaluation of Biphenylylacetic Acid-β-Cyclodextrin Conjugates as Colon Targeting Prodrugs: Drug Release Behaviour in Rat Biological Media.
    F. Hirayama, K. Minami, K. Uekama:
    J. Pharm. Pharmacol., 48, 27-31 (1996).
  285. The Interaction of Charged and Uncharged Drugs with Neutral (HP-β-CD) and Anionically Charged (SBE7-β-CD) β-Cyclodextrins.
    K. Okimoto, R.A. Rajewski, K. Uekama, J.A. Jona, V.J. Stella:
    Pharm. Res., 13, 256-264 (1996).
  286. Mass Spectroscopic Evidence on Inhibiting Effect of Maltosyl-β-cyclodextrin on Insulin Self-Association.
    K. Tokihiro, T. Irie, F. Hirayama, K. Uekama:
    Pharm. Sci., 2, 519-522 (1996).
  287. Controlled Release of Diltiazem by a Combination of Short- and Long-Chain Peracylated-β-Cyclodextrins in Dogs.
    O.A. Soliman, K. Kimura, F. Hirayama, K. Uekama, H.M. El-Sabbagh, A.H. Abd El-Gawad, F.M. Hashim:
    Pharm. Sci., 2, 533-536 (1996).
  288. Characterization of Peracylated β-Cyclodextrins with Different Chain Lengths as a Novel Sustained Release Carrier for Water-soluble Drugs.
    F. Hirayama, M. Yamanaka, T. Horikawa, K. Uekama:
    Chem. Pharm. Bull., 43, 130-136 (1995).
  289. Improvement of Dissolution Characteristics of a New Chalcone Derivative, SU-740: Comparison between Size Reduction, Solid Dispersion and Inclusion Complexation.
    S. Ito, M. Demachi, Y. Toriumi, T. Adachi, S. Itai, F. Hirayama, K. Uekama:
    Chem. Pharm. Bull., 43, 2221-2225 (1995).
  290. Enhanced Nasal Delivery of LHRH Agonist Buserelin by Oleic Acid Solubilized and Stabilized in Hydroxypropyl-β-cyclodextrin.
    K. Abe, T. Irie, K. Uekama:
    Chem. Pharm. Bull., 43, 2232-2237 (1995).
  291. Preparation of β-Cyclodextrin Sulphate-immobilized Hydrophilic Vinyl-polymer Gel as a Selective, High Recovery and Stable Adsorbent for High-Performance Affinity Chromatography of Heparin-binding Substances.
    K. Ishimura, K. Fukunaga, T. Ohta, H. Nakamura, T. Irie, K. Uekama:
    Chromatographia, 41, 349-352 (1995).
  292. Direct Measurement of High-Density Lipoprotein Cholesterol in Serum with a Combination of Polyethylene Glycol-modified Enzymes and Sulfated α-Cyclodextrin.
    H. Sugiuchi, Y. Uji, H. Okabe, T. Irie, K. Uekama, N. Kayahara, K. Miyauchi:
    Clin. Chem., 41, 717-723 (1995).
  293. Cyclodextrin Sulfates in Parenteral Use: Protection against Gentamicin Nephrotoxicity in the Rat.
    K. Shiotani, T. Irie, K. Uekama, Y. Ishimaru:
    Eur. J. Pharm. Sci., 3, 139-151 (1995).
  294. Improvement of Dissolution Characteristics of 4-Butyl-2'-carboxy-methoxy -4'-(3-methyl- 2-butenyloxy)chalcone by β-Cyclodextrin Complexation.
    S. Ito, Y. Toriumi, M. Demachi, T. Adachi, Y. Ito, H. Hayashi, F. Hirayama, K. Uekama:
    Eur. J. Pharm. Sci., 3, 323-328 (1995).
  295. Combined Use of 2-Hydroxypropyl-β-cyclodextrin and Lipophilic　Absorption Enhancer in Nasal delivery of LHRH Agonist, Buserelin Acetate in Rats.
    K. Abe, T. Irie, H. Adachi, K. Uekama:
    Int. J. Pharm., 123, 103-112 (1995).
  296. In-vivo and In-vitro Correlation for Delayed-release Behaviour of a Molsidomine/ O-Carboxymethyl-O-ethyl-β-cyclodextrin Complex in Gastric Acidity-controlled Dogs.
    T. Horikawa, F. Hirayama, K. Uekama
    J. Pharm. Pharmacol., 47, 124-127 (1995).
  297. Modification of Rectal Absorption of Morphine from Hollow-type Suppositories with a Combination of α-Cyclodextrin and Viscosity-enhancing Polysaccharide.
    K. Uekama, T. Kondo, K. Nakamura, T. Irie, K. Arakawa, M. Shibuya, J. Tanaka:
    J. Pharm. Sci., 84, 15-20 (1995).
  298. Improvement of Nasal Bioavailability of an LHRH Agonist Buserelin by Cyclodextrin Derivatives in Rats.
    K. Matsubara, K. Abe, T. Irie, K. Uekama:
    J. Pharm. Sci., 84, 1295-1300 (1995).
  299. Differential Effects of Sulfate and Sulfobutyl Ether of β-Cyclodextrin on Erythrocyte Membranes in Vitro.
    K. Shiotani, K. Uehata, T. Irie, K. Uekama, D.O. Thompson, V.J. Stella:
    Pharm. Res., 12, 77-83 (1995).
  300. Potential Use of Maltosyl-β-cyclodextrin for Inhibition of Insulin Self-association in Aqueous Solution.
    K. Tokihiro, T. Irie, K. Uekama, J. Pitha:
    Pharm. Sci., 1, 49-53 (1995).
  301. Cyclodextrin Derivatives that Modify Nasal Absorption of Morphine and Its Entry into Cerebrospinal Fluid in the Rat.
    T. Kondo, K. Nishimura, T. Irie, K. Uekama:
    Pharm. Sci., 1, 163-166 (1995).
  302. Enhanced Bioavailability and Reduced Metabolism of Salbutamol by Perbutanoyl β-cyclodextrin after Oral Administration in Dogs.
    F. Hirayama, T. Horikawa, M. Yamanaka, K. Uekama:
    Pharm. Sci., 1, 517-520 (1995).
  303. Optimal Use of Absorption Enhancer HPE-101 Solubilized in Hydroxypropyl-β-cyclodextrin for Facilitating Nasal Permeability in Rats.
    K. Abe, T. Irie, K. Uekama:
    Pharm. Sci., 1, 563-567 (1995).
  304. Percutaneous Penetration and Metabolism of Salicylic Acid Derivatives Across Hairless Mouse Skin in Diffusion Cell In Vitro.
    N. Higo, S. Sato, T. Irie, K. Uekama:
    S.T.P. Pharma Sci., 5, 302-308 (1995).